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Chromosomal rearrangements, including translocations, require formation and 
joining of DNA double strand breaks (DSBs). These events disrupt the integrity of 
the genome and are frequently involved in producing leukemias, lymphomas and 
sarcomas. Mature B cell lymphomas are unique among tumors in that they 
frequently carry clonal recurrent translocations. This may be the result of 
Activation Induced Cytidine Deaminase (AID) expression, which introduces a 
heretofore uncharacterized array of rearrangements. Despite the importance of 
these events, current understanding of their genesis is limited.  
 
To examine the origins of chromosomal rearrangements we developed 
Translocation Capture Sequencing (TC-Seq), a method to document 
chromosomal rearrangements to a fixed DSB genome-wide, in primary cells. We 
examined over 180,000 rearrangements obtained from 400 million activated B 
lymphocytes to two loci, IgH and c-myc. Our data and analysis reveal that 
  
proximity between DSBs, transcriptional activity and chromosome territories are 
key determinants of genome rearrangement. Specifically, rearrangements tend to 
occur in cis and to transcribed genes. We also find that AID induces 
rearrangement in specific hotspots. Hotspots are predominantly genic, 
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Chromosomal Translocations  
 
Chromosomal rearrangements are a variation in the normal structure of the 
genome. They may be the result of translocation, deletion, inversion or insertion; 
thereby uniting disparate parts of the genome with or without the deletion of 
intervening sequence.  Rearrangements can be physiological, as in the antibody 
diversification reactions of B lymphocytes. Or they may pathological, as in the 
Philadelphia chromosome observed in chronic myelogenous leukemia. 
 
The chromosomal translocation is a genomic rearrangement caused by the 
exchange of arms between two non-heterologous chromosomes. They are 
commonly found in leukemias, lymphomas and sarcomas and are key 
pathogenic events in cancer. Translocations can confer a survival or proliferative 
advantage upon an incipient cancer cell by: juxtaposing proto-oncogenes to 
constitutively active promoters, deleting tumor suppressors, or producing 
chimeric oncogenes (Nussenzweig and Nussenzweig, 2010). 
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Translocations are the most common class of cytogenetic abnormality in 
hematologic malignancies (Kuppers, 2005). These events are often clonal, 
indicative of their role in triggering or maintaining transformation and progression, 
and are highly stereotyped within tumor classes. Within the hematologic 
malignancies, there are classical examples of the functional and diagnostic 
implications of translocations. The Philadelphia chromosome, a translocation 
between chromosome 9 and 22 (t(9;22)(q34.1;q11.2)), is observed in chronic 
myelogenous leukemia. This rearrangement juxtaposes the 5’ region of the BCR 
gene to the 3’ region of the Abl gene generating a constitutively active tyrosine 
kinase, BCR-Abl, which drives tumor growth (Sawyers, 1993). The discovery of 
this fusion oncogene led to the successful development of diagnostic tests to 
identify the tumor, and the development of a drug to halt tumor growth in patients 
(Druker et al., 2001). Another example is Burkitt’s lymphoma, a mature B cell 
cancer associated with t(8;14)(q24;q32). This rearrangement places the 
immunoglobulin heavy chain regulatory elements next to the c-myc proto-
oncogene. c-myc is thereby over expressed, which leads to malignant 
transformation (Gostissa et al., 2009). 
 
Translocagenesis requires that three primary criteria be fulfilled.  First, paired 
DNA breaks must occur on different chromosomes (Richardson and Jasin, 2000). 
DNA damage may occur by exogenous modes such as ionizing radiation and 
chemical exposure, or by endogenous modes such as replication errors, cellular 
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metabolism and genetically programmed damage. Second, translocation partners 
must be in proximity to one another in the nucleus, a function of the three-
dimensional architecture of the genome (Roix et al., 2003). Recent studies have 
demonstrated that chromatin features, transcriptional activity, and hormone 
exposure may influence genomic architecture generally, and the proximity of 
specific translocation partners (Lieberman-Aiden et al., 2009; Mani et al., 2009). 
Finally, DSBs on heterologous chromosomes must be joined in trans (as 
opposed to faithful repair of the DSB). This is largely a function of the DNA repair 
pathway responsible for break resolution; both pathway choice and abnormalities 










Origins of DNA Double Strand Breaks 
 
The genome is under constant threat of DNA damage from both exogenous and 
endogenous sources. Damage may be the result of environmental insults, 
cellular metabolism, genomic features and development. DNA damage, if 
repaired improperly, may result in genomic rearrangement. Nearly every DNA 
damaging agent or event has been shown to lead to chromosomal 
rearrangement, and in many cases, with implications for oncogensis or other 
human diseases. 
 
 Oxidative stress. In a cell, reactive oxygen species come from multiple sources 
including UV light, aerobic metabolism, and enzymatic activity. Oxidative stress 
occurs when there is a greater abundance of these reactive oxygen species 
(ROS) than the cell’s capacity to neutralize them. If such an overabundance 
occurs, free oxidants may react with DNA to generate adducts and numerous 
downstream products including DNA breaks (Marnett, 2000). Oxide radical 
production and the resulting DNA damage has been shown to cause genomic 
rearrangements. For example, the absence of a peroxiredoxin (an antioxidant 
enzyme) in yeast causes increased frequency of chromosomal rearrangements 
(Huang and Kolodner, 2005). And, in diseases characterized by DNA repair 
defects such as xeroderma pigmentosum and ataxia telangiectasia, ROS are 




Ionizing radiation and chemical compounds. Both Ionizing radiation (IR) and 
certain chemicals may react directly with DNA, altering its chemical structure and 
resulting in damage. Ionizing radiation, defined as electromagnetic waves with 
sufficient energy to remove electrons from target atoms, causes double stranded 
DNA breaks (DSBs) at the rate of ~35 per Gy (Rogakou et al., 1998). IR-induced 
breaks are known precursors to rearrangement. For example, children exposed 
to radiation from the Chernobyl disaster suffer from high rates of papillary thyroid 
carcinoma, which bear rearrangements of the RET proto-oncogene (Fugazzola et 
al., 1995). RET rearrangements are detected in human thyroid tissue upon 
exposure to ionizing radiation, and their incidence in tissue culture is directly 
proportional to the dosage of radiation (Caudill et al., 2005).  
 
Clinically, ionizing radiation is employed in radiotherapy, where a focused beam 
is used to introduce DSBs in cancer cells, thereby inducing cell death. Ionizing 
radiation is also an essential tool for studying DNA damage in the laboratory 
setting. It has been used extensively to characterize the nature of the DNA 
damage response and the retinue of proteins that bind sites of damage. 
However, its usefulness is limited by our inability to apply irradiation in a spatially 
controlled manner.  
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Certain chemicals may also cause DNA damage. Clinically, many 
chemotherapeutic agents act in this way, thereby selectively targeting quickly 
growing cells that undergo rapid replication. For example, alkylating agents such 
as cisplatin form covalent bonds with DNA bases, generating crosslinks that elicit 
the DNA damage response, induce apoptosis, and interfere with replication 
(Lawley and Phillips, 1996). Topoisomerase inhibitors on the other hand, directly 
cause DSBs. The enzyme topoisomerase II generates then religates DSBs to 
relieve tension caused by supercoils and tangles. Rapidly dividing cancer cells 
are particularly dependent on this enzyme to facilitate replication and 
transcription. The drug etoposide binds to topoisomerase II preventing the 
religation of broken ends, thereby generating DSBs. These DSBs may serve as 
substrates for translocation (Libura et al., 2005). For example, TOP2 inhibition 
has been shown to generate breaks in the mixed lineage leukemia (MLL) cluster 
region. Patients treated for acute lymphoblastic leukemia (ALL) with TOP2 
inhibitors may thereafter suffer rearrangement of the MLL gene, which can lead 
to therapy-related acute myeloid leukemias (Blanco et al., 2001). 
 
Replicative stress. During DNA replication, stalling of replication forks may be the 
result of sequence features such as repeat rich sequences, loci with complex 
secondary structure, nucleotide deficiency, assorted forms of DNA damage or 
collisions between replication and transcription machinery (Mani and Chinnaiyan, 
2010). Normally, fork stalling leads to ssDNA generation that affects downstream 
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fork repair and checkpoint activation (Allen et al., 2011). An unrepaired 
replication fork however, may give rise to unusual DNA structures and collapse 
into a double strand break, a phenomenon that may also occur upon a fork 
encounter with a single strand nick (Ammazzalorso et al., 2010). 
 
DNA breaks originating from replication fork collapse may serve as intermediates 
in the formation of complex chromosomal rearrangements, structures that involve 
reorganization of sequence from breakpoints on three or more chromosomes. It 
has been proposed that broken 3’ ends from collapsed replication forks anneal to 
extra-chromosomal single stranded DNA based on homology. Annealed ssDNAs 
then polymerize, and in a series of template changes followed by the continuation 
of replication, complex chromosomal rearrangements are formed (Hastings et al., 
2009). These structures have been observed in female patients suffering from 
multiple recurrent abortions and in male patients with hypospermatogenesis or 
spermatogenic arrest (Kim et al., 2011). 
 
Common fragile sites. In 1984 Glover and collegues notes that when aphidicolin 
(an inhibitor of DNA polymerase) is added to a cell culture, chromosomes 
develop non-random gaps on metaphase spreads. These gaps became more 
frequent with folic acid deprivation and appeared to match gaps found by 
previous studies of spontaneous chromosomal damage (albeit at a much lower 
frequency). The breaks were present in 12 of 12 cultures tested so they were 
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termed common fragile sites (Glover et al., 1984), and they were attributed to 
conditions of partial replicative stress. About 80 of these sites are currently 
known, however, they are coarsely mapped; generally they are only localized to 
chromosome bands. A sequence feature is very likely to underlie this 
phenomenon, but the exact cause of their emergence is unknown. Common 
fragile sites examined to date are mainly AT-rich sequences (Zlotorynski et al., 
2003). And, it has been hypothesized that fragile sites appear in late replicating 
regions of the genome (Dillon et al., 2010). It is also possible that fragile sites 
represent long regions of ssDNA that tend to form secondary structures, leading 
to replication fork stalling and collapse (Dillon et al., 2010).  
 
DSBs resulting from common fragile sites have been implicated in the formation 
of chromosomal rearrangements. In a study that examined all known cancer-
associated recurrent translocations, 52% occurred within known fragile site 
positions (Burrow et al., 2009). In one specific case, the most frequently 
expressed fragile site in the human genome, FRA3B, is located within the tumor 
suppressor gene FHIT (Huebner and Croce, 2001). Deletions of FHIT are 
associated with cancer of the breast, lung, cervix, and esophagus.  
 
Transcriptional stress. Transcription induces a multitude of changes on the DNA. 
It may change DNA conformation, strandedness, position and the local milieu of 
proteins. Additionally, it may interact with existing processes on the DNA such as 
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replication or DNA repair and with lesions such as altered bases. As a 
consequence of these changes and interactions, transcription can compromise 
genomic stability in the form of increased mutation and recombination rates. 
 
The phenomenon of transcription-associated mutation was first described 40 
years ago by studies in prokaryotes. In E. coli, alkylating agent induced mutation 
of the β-galactosidase gene is stimulated by transcription (Brock, 1971). And, in 
the presence of acridine (a mutagen) lac null mutations are reverted more 
frequently in the presence of transcription (Herman and Dworkin, 1971). The 
persistence of ssDNA at the transcription bubble may account for this instability; 
many mutagenic reactions are more efficient on ssDNA than dsDNA (Aguilera, 
2002). For example, in bacteria, spontaneous deamination of cytosine is 140-fold 
more efficient on ssDNA than on dsDNA (Frederico et al., 1990). And, in E. Coli 
mutation of LacI and human hprt is more prominent on the non-transcribed strand 
(which is open ssDNA) as compared to the transcribed strand (which is in 
complex with RNA and multiple proteins) (Fix and Glickman, 1987). Finally, with 
an RNA polymerase mutant characterized as having a slow elongation rate 
transcription-associated mutation is higher than with a wild type polymerase. This 
may suggest that mutations rates depend on the length of time that DNA is held 
in an open, single stranded conformation (Beletskii et al., 2000).  
 
In addition to increasing mutation rates, transcription appears to boost 
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recombination rates as well. Evidence for transcriptionally active recombinogenic 
DNA in eukaryotes was first described in the context of recombination hotspots, 
high levels of recombination were observed between nearby genes in the hotspot 
HOT1 (in the ribosomal RNA genes) (Keil and Roeder, 1984). Later work showed 
that transcription by RNA polymerase I was responsible and required for the 
recombination (Voelkel-Meiman et al., 1987). Eventually, this phenomenon was 
shown in regions transcribed by RNA Polymerase II; transcription enhanced 
recombination 15 fold between directly repeated sequences of GAL10 in S. 
cerevisiae (Thomas and Rothstein, 1989). 
 
In 1990, Nickoloff and colleagues provided the first evidence for transcription 
associated recombination in mammalian cells. They found that transcription 
between heteroallelic neomycin genes on extrachromosomal plasmids was 
significantly stimulated in the presence of transcription (Nickoloff and Reynolds, 
1990); the same effect was shown with intra-chromosomal recombination of 
integrated substrates (Nickoloff, 1992). Interestingly, transcription does not 
appear to increase the frequency of DSB induced recombination and does not 
change the spectrum of recombination events from a DSB. For example, when 
an I-SceI break is introduced in a direct repeat of a neo gene, transcription does 
not change the frequency of recombination between repeats, the repair pathway 
used or the size of deletions at the break (Allen et al., 2003). This suggests that 
transcription may be enhancing the generation of recombinogenic lesions, not 
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enhancing the recombinogenicity of existing lesions. Of note, transcription 
enhances the use of a donor sequence in DSB-induced recombination 
(Schildkraut et al., 2006).  
 
There are several theories to explain the phenomenon of transcription-associated 
recombination. First, transcription may expose ssDNA that is more prone to 
damage and thereby, recombination. Given the propensity of transcription-
associated mutations to occur on the exposed single strand of the transcription 
bubble, one might reason that this is a likely mechanism for recombination as 
well (Aguilera, 2002). In cells treated with a carcinogen 4-nitroquiniline-N-oxide 
transcription appears to synergize with DNA damage to drive recombination 
frequencies distantly above background levels (>4000 fold) (Garcia-Rubio et al., 
2003). This suggests that transcription indeed increases the availability of DNA, 
and perhaps ssDNA, for damage and recombination. However, to our knowledge 
it has never been directly shown that recombination is more likely to occur to 
regions of ssDNA.  
 
Another non-mutually exclusive possibility is that transcription associated 
recombination might be caused by replication fork/transcription bubble collisions. 
Replication and transcription can take place on the same strand at the same 
time; these processes might obstruct one another, resulting in stalled and 
collapsed replication forks. These events may result in rearrangement. For 
 12 
example, when replication and transcription are initiated in opposite directions on 
an extrachromosomal substrate in E coli, up to 12 percent of the isolated plasmid 
sustains deletions (Vilette et al., 1996). In this situation, the replication fork has 
been shown to stall for several minutes, which may result in collapse and ensuing 
damage (Liu and Alberts, 1995). Supporting this model of transcription 
associated recombination Gottipati and colleagues have shown that the 
phenomenon tends to occur in S phase, suggesting that it is dependent on 
replication (Gottipati et al., 2008) 
 
Genetically programmed DSBs. During T and B lymphocyte development, 
antigen receptor diversification occurs by virtue of specific DNA breaks and 
recombination events. The enzymes responsible for generating these breaks 
may contribute to genomic instability via promiscuous joining of physiological 
DSBs and generation of off-target DSBs. V(D)J recombination, catalyzed by a 
site-specific nuclease RAG1/2, generates antigen receptor variable region 
diversity by combining gene segments in myriad permutations. RAG1/2 
introduces nicks at recombination signal sequences that convert to double strand 
breaks by transesterification (Roth, 2003). Unresolved ends from RAG breaks in 
the immunoglobulin loci may partner with other DSBs to generate oncogenic 
rearrangements, as in the bcl-2/IgH translocation observed in follicular lymphoma 
(Jager et al., 2000). Additionally, RAGs can function as a transposase, which 
may be a means for rearrangement production (Brandt and Roth, 2004). They 
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may also introduce breaks in various non-antigen receptor loci including those 
bearing non-B DNA structures or cryptic recombination signal sequences 
(Raghavan et al., 2001; Raghavan et al., 2004). However, the extent of these 
non-Ig breaks and their locations remain unknown. 
 
Mature B cells suffer genomic insult from two additional diversification reactions 
catalyzed by Activation Induced Cytidine Deaminase (AID). Somatic 
hypermutation introduces non-templated mutations in the immunoglobulin genes 
during B cell activation in the germinal center. Class switch recombination 
changes the immunoglobulin constant region in a deletional recombination 
reaction catalyzed by double strand breaks in switch regions. In addition to acting 
on physiological targets, AID may generate DSBs throughout the genome 
(Nussenzweig and Nussenzweig, 2010). V(D)J recombination, somatic 
hypermutation and class switch recombination will be discussed in greater detail 
in later sections. 
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DNA Repair Pathways in Translocagenesis 
 
Maintaining genomic integrity is key to cellular survival and proliferation. As such, 
multiple DNA repair pathways have evolved to recognize and repair DNA 
damage. Depending on the repair pathway, DNA breaks may be rejoined 
faithfully or may generate rearrangements. Additionally, defects in a pathway 
may result in unfaithful break repair. There are three major DNA repair pathways 
thought to repair DSBs; homologous recombination (HR), non-homologous end 
joining (NHEJ) and alternative non-homologous end joining (Alt-NHEJ). 
 
Homologous recombination. HR is a primary pathway in the S and G2 phase of 
the cell cycle, during which time it repairs DSBs by using a sister chromatid 
template. In this pathway DNA ends must first be resected by exonucleases, 
leaving a 3’ single stranded end. Exposed ssDNA is then bound by Replication 
Protein A (RPA) and Rad51 to form a nucleoprotein filament. This process also 
requires the MRN complex, BRCA1 and BRCA2. The filament carries out a 
homology search eventually forming a displacement loop on a homologous 
sequence. The invading strand then copies sequence from the template strand. 




Homologous recombination plays an important role in maintaining genomic 
integrity; if the pathway is fractured cells suffer an increase in genomic instability 
(Sonoda et al., 1998). Specifically, in the absence of HR cells exhibit an increase 
of double strand breaks at fragile sites (Schwartz et al., 2005). Loss of certain HR 
components may also result in the accumulation of genomic abnormalities. For 
example, the loss of BRCA1 or BRCA2 leads to chromosomal radial structures, 
which are fusions between different chromosomes (Patel et al., 1998). Radial 
structures may break during mitosis resulting in breakage-bridge fusion cycles 
that give rise to translocations. Finally, loss of BRCA1 function is observed in 
inherited breast cancer, indicating the importance of this pathway in preventing 
oncogensis (Ford et al., 1994). 
 
Non-homologous end joining. NHEJ is the so-called “error prone” repair pathway, 
which may occur throughout the cell cycle, but predominantly in G1 (Takata et 
al., 1998). Breaks are repaired by simply reattaching the ends, rather than 
copying from a homologous strand, so bases may be lost or mutated at the 
junctions. Briefly, in this pathway Ku70-Ku80 heterodimers bind the broken ends, 
which recruits DNA dependent protein kinase catalytic subunit (DNA-PKcs) to 
form a synaptic complex. Thereafter, the LigaseIV-Xrcc4 complex religates the 
broken ends (Lieber, 2008). Ataxia-telangiectasia mutated protein (ATM), a 
serine/threonine kinase, is responsible for phosphorylating numerous DNA repair 
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effectors, cell cycle checkpoint proteins and for amplifying the DNA damage 
signal (Derheimer and Kastan, 2010).  
 
The classical NHEJ factors are required for faithful DSB repair, V(D)J 
recombination, and for efficient class switch recombination (Manis et al., 2002; 
Nussenzweig et al., 1996; Zhu et al., 1996). In the absence of NHEJ factors, 
there is a dramatic increase in persistent DSBs and chromosomal 
rearrangements (Difilippantonio et al., 2000). So, NHEJ suppresses aberrant 
rejoining events, including translocations, while encouraging appropriate intra-
chromosomal repair. Consistent with this idea, translocations generated by 
RAGs, AID and homing endonucleases do not require the NHEJ factors Ku70, 
Ku80, DNA-PKcs or XRCC4, rather, translocation formation is increased in their 
absence (Boboila et al., 2010a; Callen et al., 2009; Wang et al., 2009; Weinstock 
et al., 2007). An intact NHEJ pathway is also required to suppress oncogensis. 
For example, mice lacking p53 and Ku80 develop early onset pro-B cell 
lymphomas characterized by recurrent chromosomal translocations 
(Difilippantonio et al., 2000). 
 
Alternative non-homologous end joining. Alt-NHEJ is a poorly defined pathway, 
but is likely of great importance in generating chromosomal rearrangements. Alt-
NHEJ is primarily characterized by presence of microhomology (~>4 nucleotides) 
and deletion at the repaired junction, beyond what is normally observed at 
 17 
junctions generated by the NHEJ pathway (Lieber, 2008). The presence of 
microhomology at junctions was first described in 1986 (Roth and Wilson, 1986). 
Since then, the existence of a specific pathway has been demonstrated (Yan et 
al., 2007). While Alt-NHEJ is most robust in cells with a disabled classical NHEJ, 
it appears to perform repair even in the presence of an intact NHEJ pathway 
(Corneo et al., 2007). Several proteins have been implicated in Alt-NHEJ, 
including Mre11 and CtIP, which are notable for their involvement in end 
resection and ssDNA generation (Bennardo et al., 2008; Deriano et al., 2009; 
Lee-Theilen et al., 2011).  
 
Alt-NHEJ appears to play a role in chromosomal translocation. In the absence of 
NHEJ factors Ku70 and Ligase4 or Xrcc4 and Ligase4, breaks are more likely to 
partner in translocations, and the junctions of those events bear microhomologies 
– indicating the role of alt-NHEJ in their formation (Boboila et al., 2010a; Simsek 
and Jasin, 2010). Additional evidence can be found in a mouse model of RAG-
mediated lymphomagenesis. Deriano and colleagues generated mice that lack 
p53 and express a truncated form of RAG2, coreRAG2. coreRAG2 releases DNA 
ends after cleavage, allowing them to be accessed and repaired by the alt-NHEJ 
pathway (Corneo et al., 2007). These mice develop lymphomas bearing 
chromosomal rearrangements showing: the role of alt-NHEJ in generating 
genomic abnormalities, the importance of those abnormalities in 
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lymphomagenesis, and the role classical NHEJ plays in suppressing 
rearrangements and oncogensis (Deriano et al., 2011). 
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Spatial Proximity in Translocagenesis 
 
To form a rearrangement DSBs must be in proximity to one another. The 
proximity of two loci may be impacted by several factors including the 
constitutional architecture of the genome, transcription, chromatin accessibility 
and signaling pathways. While the 3D structure and dynamics of the genome are 
still emerging there appear to be certain principles dictating its form and, they 
may exert effects on the genomic rearrangement landscape. 
 
1st order genomic architecture: chromosome territories. An organization of 
interphase chromosomes was first proposed in the 19th century, and Theodore 
Boveri coined the term chromosome territory in 1909. In Boveri’s studies of the 
horse roundworm blastomere he noted that chromosome ends protruding from 
the nucleus maintained their position as the cell transitioned from prophase, 
during which individual chromosomes are visible, to interphase. He concluded 
that the chromosome territory is stably maintained during the cell cycle (Cremer 
and Cremer, 2010). Subsequent light microscopy studies supported these 
assertions (Stack et al., 1977), but in electron micrographs of the nucleus 




Recent studies have resurrected the concept of chromosome territories. Direct 
visual evidence was first obtained by in situ hybridization on total human DNA in 
cell hybrids containing only one human chromosome on a background of 
Chinese hamster ovary chromosomes (Manuelidis, 1985). Indeed, individual 
human chromosomes could be delineated during interphase. The advent of 3D 
fluorescent in situ hybridization and specific probes has allowed higher resolution 
studies of chromosome territories. These have confirmed their existence. For 
example, differential coloring of all 24 chromosomes in human fibroblasts 
followed by serial sections of laser confocal microscopy images showed excellent 
separation of distinct chromosome territories (Bolzer et al., 2005).  
 
High throughput DNA sequencing has provided yet another tool for examining 
nuclear structure. In 2009 Lieberman-Aiden and colleagues developed Hi-C (High 
throughput chromosome conformation capture). In Hi-C, cells are cross-linked (to 
preserve long-rage chromatin interactions) then DNA is digested with restriction 
endonucleases. Ends are filled in with biotinylated nucleotides and the resulting 
blunt fragments are ligated under dilute conditions that promote ligation between 
cross-linked DNA fragments. The result is a pool in which fragments of DNA 
residing in close nuclear proximity are ligated and marked with a biotin. A high 
throughput paired-end library is assembled from biotinylated fragments, 
sequenced, and a catalog of nuclear interactions is developed. This study 
showed that intra-chromosomal contacts are more likely than trans-chromosomal 
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contacts, indicating the presence of chromosome territories (Figure 1.1) 
(Lieberman-Aiden et al., 2009). 
 
 
Adapted from Lieberman-Aiden et al., 2009 
 
Figure 1.1. Hi-C data indicates the presence of chromosome territories. The 
probability of intra-chromosomal contact between DNA fragments (solid line) 
exceeds the probability of trans-chromosomal contact (dotted lines) at any 
distance between fragments mapping to the same chromosome (Lieberman-
Aiden et al., 2009). 
 
 
The existence of chromosome territories may impact the rearrangement 
landscape across the genome. A 2009 report from Mahowald and colleagues 
demonstrated a system for cloning breakpoints from aberrantly resolved RAG 
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DSBs generated during V(D)J recombination in Atm-/- Abelson transformed pre-B 
cells. They showed that 60% of rearrangements occur to points on the same 
chromosome as the recombination substrate, rather than to trans-chromosomal 
targets. And, of these intra-chromosomal targets 87% were within 200kb of the 
recombination substrate. This study suggests that intra-chromosomal joining may 
be preferred to trans-chromosomal joining, however, they examined a small 
number of rearrangements limiting the certainty of the results (Mahowald et al., 
2009). Firm proof that chromosome territories influence the landscape of 
rearrangements is still lacking, and whether this phenomenon occurs locally or 
over the entire chromosome is unknown. For this issue to be addressed, a much 
greater quantity of data is required in primary cells. 
 
2nd order genomic architecture: functional compartments. In the interphase 
nucleus perhaps the most obvious forms of nuclear organization are the 
heterochromatic and euchromatic compartments. These compartments, which 
are easily visible by light microscopy, represent transcriptionally active open 
chromatin and transcriptionally inactive closed chromatin. In eukaryotes, 
heterochromatin tends toward the nuclear envelope while euchromatin lies 
centrally in the nucleus, and this organization relates to gene activation. For 
example, immunoglobulin loci only active in pro-B cells are positioned at the 
nuclear periphery in pro-T cells and hematopoietic precursors, but are centrally 
located in pro-B cell nuclei (Kosak et al., 2002). And, active and inactive alleles of 
 23 
a mono-allelicly expressed astrocyte specific protein, GFAP, occupy different 
subnuclear compartments and radial positions in the nucleus depending on their 
functional status (Takizawa et al., 2008). These observations suggest that 
transcriptional activity is a mediator of genome organization.  
 
Hi-C revealed transcription- and chromatin conformation-dependent levels of 
genome organization. First, gene rich chromosomes interact with one another. 
This suggests that in regard to chromosome relationships, genes influence the 
nuclear position. Hi-C data analysis also revealed two general spatial 
compartments within the nucleus. The presence of genes, hypersensitivity to 
DNAseI and high transcription levels (as measured by mRNA levels) accounted 
for the differences between these two compartments. Thus, the genome consists 
of two neighborhoods; active and inactive loci (Lieberman-Aiden et al., 2009). 
Whether this level of organization impacts the genomic rearrangement profile or 
the joining behavior of specific breaks remains unclear. Some bias for genic 
rearrangements has been demonstrated in deep sequencing experiments on 
human tumors (as will be discussed at the end of this section). However, 
rearrangements in tumors may be selected or a function of some cancer specific 
joining aberration, so it is difficult to draw general conclusions about the nature of 
rearrangements from these studies. 
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Proximity of specific partners. The importance of proximity in rearrangement 
propensity is demonstrated by studies of specific oncogenic rearrangement 
partners. Average proximity of loci correlates with their rearrangement frequency, 
indicating that proximity is a determinant of translocation. For example, Burkitt’s 
lymphoma is characterized by translocations involving c-myc. Clinically, c-myc 
fusion to the immunoglobulin heavy chain (IgH) is common, while fusion to the 
immunoglobulin light chain kappa (IgK) is infrequent (Roix et al., 2003). In 
experiments using FISH in a cytogenetically normal B-lymphoblast cell line, Roix 
and colleagues demonstrated that c-myc is in closer proximity to IgH than IgK 
(Roix et al., 2003). In the same study, similar relationships were described for 
other translocation partners. This suggests that proximity might dictate 
rearrangement propensity. 
 
Many rearrangements are cell-type specific. The proximity of specific 
translocation partners is also cell-type specific and related to the occurrence of 
rearrangement. For example, he BCR-Abl fusion of chronic myelogenous 
leukemia occurs in an early hematopoietic stem cell while the promyelocytic 
leukemia protein (PML) – retinoic acid receptor alpha (RAR-alpha) fusion of 
acute promyelocytic leukemia occurs in committed hematopoietic precursors 
(Mani and Chinnaiyan, 2010). In a population of cells containing early 
hematopoietic stem cells, BCR and Abl are in close proximity while PML and 
RAR-alpha are not (Neves et al., 1999). This is further evidence that proximity is 
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a determinant of rearrangement and suggests that the cell-type specificity of 
rearrangements may be a function of partner locus proximity.  
 
Signaling pathways within an individual cell type may also influence the proximity 
of partner loci, and thereby effect rearrangement generation. This phenomenon 
can be observed in the ETS gene rearrangements that fuel prostate cancer. 
These rearrangements yield fusions of the 5’ UTR of an androgen-regulated 
gene with ETS family genes (ERG, ETV1, ETV4, ETV5); of these, TMPRSS2-
ERG is the most common (Helgeson et al., 2008; Lin et al., 2009). Treating 
human prostate cancer cells with dihydrotestosterone (DHT) induces proximity 
between these partners by a myosin and actin dependent mechanism (Mani et 
al., 2009). When subjected to irradiation, these cells then form TMPRSS2-ERG 
rearrangements. The authors of this study conclude that signaling pathways can 
effect the position of certain rearrangement partners. This phenomenon may play 
an important role in the formation of recurrent chromosomal aberrations. 
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Next Generation Analysis of Rearrangements in Tumors.  
 
Next generation sequencing technologies have facilitated the in depth 
examination of cancer genomes. These technologies enable the generation of 
transcriptome, methylome, genome and epigenetic maps. Of particular relevance 
to this study, cancer genome sequences have provided a high-resolution view of 
some cytogenetic abnormalities in human cancer. While the events sequenced 
from tumors are highly selected, and may be formed by aberrant cancer-cell 
specific mechanisms, the landscape of rearrangements in cancer may reveal 
some principles of chromosomal rearrangement. 
 
Rearrangements in tumors may be examined by transcriptome sequencing of 
cDNA. This limits the number of reads required to achieve complete coverage, 
and thereby limits the cost of analysis; however, only a small fraction of the 
genome can be viewed. In a study of the breast cancer cell line HCC1954 this 
technique was successfully employed to discover novel rearrangements. By 
mining the sequencing data for chimeric reads (those mapping to two disparate 
loci), Zhao et al discovered 7 cDNAs representing 6 transchromosomal events 
and 1 intrachromosomal event, all of which could be confirmed by FISH, genomic 
DNA PCR or cDNA PCR (Zhao et al., 2009). Some events appeared to have 
oncogenic significance. For example, they found truncating translocation of 
MRE11A, a protein involved in DNA repair. And, a translocation of NSD1 (a gene 
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fusion partner in acute myeloid leukemia) was found to an intergenic sequence 
on chromosome 8 (Zhao et al., 2009). This approach can successfully discover 
some cytogenetic abnormalities. Unfortunately, the limited number of 
rearrangements obtained does not provide sufficient power to make any 
conclusions about the global rearrangement profile of this line or the general 
principles guiding rearrangement formation.  
 
Whole genome paired-end sequencing provided a more comprehensive analysis 
of rearrangements. Paired-end genome sequencing involves reading both sides 
of all randomly generated 200 bp genomic DNA fragments, thereby providing a 
complete genome sequence as well as the location of any structural variations. In 
the sequences of 2 lung cancer cell lines, Campbell and colleagues discovered 
103 somatically acquired rearrangements. Having such a number of 
rearrangements allowed the extraction of some general trends: rearrangements 
tended to originate from amplicons and rearrangements predominantly occur 
intra-chromosomally. Of the 103 events isolated, 81 were intra-chromosomal 
(Campbell et al., 2008). A subsequent study that captured 2,166 rearrangements 
by analyzing 24 breast cancer genomes added additional power to these 
analyses. Of more than 2,000 events, 1,708 were intra-chromosomal, and of 
these, 1,574 showed breakpoints within 2Mb of one another (Stephens et al., 
2009). Paired-end sequencing of metastatic pancreatic cancer revealed a similar 
bias toward intra-chromosomal events (Campbell et al., 2010). This may suggest 
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that a) linear physical proximity encourages rearrangement, and b) chromosome 
territories might be a determinant of rearrangement. However, since these 
rearrangement profiles are from tumors, they may not be generalized to a normal 
cell.  
 
The breast cancer genome sequence also revealed that 50% of rearrangements 
occur in genic regions (Stephens et al., 2009). This is significantly more than 
expected to occur in genic regions, which compose just 40% of the genome. 
However, rearrangements near genes are likely to alter gene expression or 
function and impact proliferative or metabolic capacity. So, whether this finding 
represented a bona fide predisposition to intragenic rearrangement or a 
consequence of selection could not be determined.  
 
Analysis of the rearrangement junctions from breast cancer genomes showed 
that the majority had minor junctional microhomology, and 5-15% of the junctions 
used greater than 4 nucleotides (Stephens et al., 2009). This implicates both 
NHEJ and alt-NHEJ as the primary pathways generating rearrangements based 
on microhomology utilization. However, nucleotide deletion from a break is 
another important parameter in the joining process, and in this approach the 
extent of end deletion cannot be assessed because the precise breakpoints were 
unknown. 
 29 
Mature B Cell Lymphomas  
 
The yearly incidence of lymphoma is about 2 per 10,000; this represents 5% of 
all cancers in the US. About 95% of these cases are cancers of mature B cell 
origin (Kuppers, 2005). While nearly all cancers carry cytogenetic abnormalities, 
the mature B cell cancers distinguish themselves by their tendency to carry 
clonal, recurrent translocations that drive tumor growth. This predisposition to 
oncogenic rearrangement may be due to a relatively high DNA damage burden. 
Mature B cells divide rapidly and so are prone to an increased frequency of usual 
genomic insults. Perhaps more significantly, mature B cells express Activation 
Induced Cytidine Deaminase (AID) that normally introduces DNA damage in 
immunoglobulin genes to facilitate the antibody diversification reactions class 
switch recombination and somatic hypermutation. However, AID activity may also 





Mature B Cell Lymphoma Origins and Pathogenesis 
 
Developed B cells participate in the humeral immune response by producing 
antibodies to recognize and bind antigen. However, B cells must first complete a 
complex developmental program that includes de novo antigen receptor 
construction, activation, and affinity maturation. Development begins in the bone 
marrow with V(D)J recombination, which assembles the immunoglobulin heavy 
and light chain genes to form an antigen binding B cell receptor, the precursor to 
a secreted antibody. This process is performed at the DNA level and involves 
permanent alteration of the B cell genome. After presentation of a functional B 
cell receptor (BCR) on the surface, mature naïve B cells leave the bone marrow 
and home to the peripheral lymphoid organs where they form germinal centers. 
In germinal centers, mature naïve B cells may be activated by T cell dependent 
or independent mechanisms to expand, express AID, and undergo the 
immunoglobulin diversification reactions somatic hypermutation (SHM) and class 
switch recombination (CSR) (Durandy, 2003). These reactions alter the affinity of 
the BCR for its cognate antigen and change the effector function of the resulting 
antibody, respectively. B cell cancers can arise at any stage of development. 
 
Origins of mature B cell lymphomas. B cell lymphomas can be traced to a cellular 
origin based on the B cell developmental stage they most closely resemble 
(Kuppers, 2005). Mature B cells lymphomas are so called because they originate 
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from B cells at this late stage of development, and therefore, show many of the 
characteristics of mature B cells. For example, Burkitt’s lymphoma cells strongly 
express usual germinal cell B cell surface markers CD19, CD20 and CD22, while 
follicular lymphoma grows in follicles reminiscent of the germinal center 
morphology (Bellan et al., 2010; Carbone et al., 2009). In fact, the majority of 
mature B cell lymphomas are thought to derive from germinal center or post-
germinal center cells. Consistent with this, the mature B cell lymphomas follicular 
lymphoma, Burkitt's lymphoma, diffuse large-cell lymphomas, MALT lymphoma 
and multiple myeloma all have hypermutated variable regions, indicating AID 
activity (and thereby germinal center residence) during or before malignant 
transformation (Kuppers et al., 1999). Some of the mature B cell lymphomas, 
such as follicular lymphoma, even exhibit ongoing somatic hypermutation, 
bolstering the case for their germinal center parentage (Bahler and Levy, 1992). 
 
More recently, gene expression profiling has supplanted more traditional modes 
of tumor characterization such as selected cell surface markers and histological 
appearance. By profiling normal B cell subsets along with tumors then comparing 
their gene signatures, the origins of these lymphomas can be further elucidated. 
Using this method, follicular lymphoma, Burkitt’s lymphoma and most diffuse 
large B cell lymphomas were shown to have a GC B cell gene expression 
signature (Alizadeh et al., 2000). Interestingly, a subset of diffuse large cell 
lymphoma (the activated B like DLBCL) most closely resembled in vitro activated 
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B cells. It should be noted that malignant transformation might change gene 
expression profiles and mask the true origin of tumors. However, together with 
the observation that many of these tumors carry mutated variable regions, these 
data strongly suggest that the mature B cell lymphomas indeed originate from 
GC or post-GC cells. 
 
Genetic lesions in mature B cell lymphoma. B cell lymphomas are unique among 
cancers in that they almost all carry chromosomal translocations. Most of these 
rearrangements involve one of the immunoglobulin loci and an oncogene (Table 
1.1). Consequently, the oncogene is brought under control of the immunoglobulin 
transcriptional regulatory elements thereby dysregulating its expression. For 
example, in diffuse large B cell lymphoma the IgH regulatory elements may 
partner with the BCL2 locus to form the IgH/BCL2 translocation. The BCL2 
protein (an antiapoptosis factor) is constitutively expressed, which prevents cell 
death (Weiss et al., 1987) In Burkitt’s lymphoma c-myc become constitutively 
expressed and drives uncontrolled cell proliferation (Dalla-Favera et al., 1983). In 
the mature B cell lymphomas unregulated expression of an oncogene is 
frequently coupled with deletion or inactivation of a tumor suppressor. In other 
words, a translocation provides cancer’s accelerator, while deletion or mutation 
takes away the brakes. For example, in mantle cell lymphoma ATM is frequently 
mutated, this disables the DNA damage response and prevents the cell from 
blocking cell cycle progression in the case of genomic insult (Camacho et al., 
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2002). And, in Burkitt’s lymphoma p53 is mutated in nearly 50% of the cases 
(Gaidano et al., 1991). 
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Mantle cell lymphoma CCND1-IgH (95) ATM (40) 
 
Follicular lymphoma BCL2-IgH (90)  
 









Burkitt’s lymphoma c-myc-IgH/IgL (100) p53 (40) 
RB2 (20-80) 
 









PAX5-Igh (50)  






Table 1.1. Genomic abnormalities in mature B cell lymphomas. Each mature 
B cell lymphoma subtype is shown with its associated chromosomal 
translocation(s) and tumor suppressor gene mutation(s). In parentheses are the 
percent of all cases in which the abnormality is estimated to exist. Adapted from 
(Kuppers, 2005). 
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Of the three immunoglobulin loci, the heavy chain locus most frequently serves 
as a translocation partner. IgH is subject to all three of the antibody diversification 
reactions, and these reactions may generate the DSBs that serve as substrates 
for translocation (more on this in later sections). However, translocagenesis 
requires paired double strand breaks, and the origin of oncogene DSBs in mature 
B cell lymphomas has been much debated. The recurrent nature of 
translocations associated with mature B cell lymphomas might simply be a result 
of random events that are strongly selected. This must certainly be part of the 
picture whereas tumorigenesis requires a sustained selective advantage. 
However, oncogenes may also suffer specific recurrent targeted DSBs, as does 




Programmed DSBs in B Lymphocytes 
 
B cells produce an antibody of two identical heavy and light chains. The heavy 
chains are connected to one another and to the light chains by disulfide bonds. 
The C-terminal portions of the heavy chains are called the constant region and 
are responsible for antibody effector functions. The N-terminal portions of the 
heavy and light chains compose the antigen-binding site or variable region 
(Figure 1.2). Antibodies recognize antigen in an effort to neutralize and mount a 
response to pathogens. However, a finite genome cannot code for a sufficient 
diversity of antigen receptors. B cells create this diversity de novo by somatic 
gene alteration in three reactions: V(D)J Recombination, Class Switch 
Recombination (CSR) and Somatic Hypermutation (SHM). Two of these 
reactions, CSR and V(D)J Recombination, involve DSB intermediates. 
 
V(D)J Recombination. V(D)J recombination can be thought of as a “Pick 3 
Lottery” where gene segments are combined in assorted permutations to 
generate the variable region of antibodies. It is a site-specific recombination 
reaction that, in B cells, occurs between immunoglobulin gene segments flanked 
by recombination signal sequences (RSSs). RSSs consist of a conserved 
heptamer and nonamer separated by either 12 or 23 bp of nonconserved 
sequence. Recombination reactions may only occur between 12- and 23-RSSs 
(van Gent et al., 1996). V(D)J is initiated by DSBs located between the gene 
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segment and its RSS. RSSs are joined to form signal sequences while gene 
segments are joined in a process that involves the alteration of sequences at the 




         A                                                   B 
 
Adapted from (Bothmer, 2011) 
 
Figure 1.2. Schematic of an antibody. (A) Antibodies are composed of two 
identical heavy (blue) and light (green) chains connected by disulfide bonds. (B) 
The C-terminal portions of the heavy chains are called the constant region 




In B cells, V(D)J recombination occurs on the immunoglobulin heavy (IgH) and 
light chain loci. In mice, IgH consists of hundreds of V, 13 D and 4 J gene 
segments over a ~ 1 Mb region on chromosome 12. There are 2 light chain loci, 
IgKappa and IgLambda, which only contain V and J segments. B cell 
development begins in the bone marrow where pro-B cells undergo D-J 
rearrangement followed by V-DJ rearrangement on IgH. They are now pre-B 
cells, which undergo V-J rearrangement on the light chain and develop into 
immature B cells.  
 
V(D)J is catalyzed by the RAG1 and RAG2 gene products. RAGs introduce a 
nick between two coding sequences and their RSSs, then catalyze a 
transesterification reaction in which the 3’ hydroxyl group on the coding strand 
forms closed hairpin coding ends and blunt signal ends (McBlane et al., 1995). 
This process generates 4 ends that remain associated with RAGs in a post-
cleavage complex (Qiu et al., 2001; Tsai et al., 2002). Both signal ends and 
coding ends are joined by the NHEJ machinery, requiring the activity of Ku70, 
Ku80, XRCC4 and Ligase4 (Roth, 2003). However, before the coding ends are 
joined, the endonuclease Artemis opens the hairpins to generate a substrate for 
nucleotide addition by terminal deoxynucleotidyl transferase (TdT) (Komori et al., 
1993; Ma et al., 2002). The absence of any NHEJ factors leads to the complete 
lack of V(D)J recombination and the severe-combined immunodeficiency 
phenotype (Frank et al., 1998; Gu et al., 1997; Nussenzweig et al., 1996; Taccioli 
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et al., 1993). 
 
The RAG post cleavage complex is thought to shepherd the ends to joining via 
the NHEJ pathway, excluding access to the ends by alt-NHEJ. This function is 
mediated by RAG2, which plays an important role in protecting RAG-generated 
ends from generating oncogenic rearrangements (Corneo et al., 2007; Deriano et 
al., 2011). 
 
Overview of Class Switch Recombination. After antigen receptor assembly, B 
cells home to the peripheral lymphoid organs where they may undergo Class 
Switch Recombination (CSR). CSR is a deletional recombination event that 
exchanges an IgH constant region gene for one of several others. The constant 
region of an antibody (or isotype) determines its effector function. For example, 
IgG1 can activate complement while IgE causes leukocyte degranulation. In mice 
there are 8 constant regions: Cμ, Cδ, Cγ3, Cγ1, Cγ2b, Cγ2a, Cε and Cα. Naive 
B cells transcribe the Cμ constant region and express cell-surface IgM (IgD is 
expressed by virtue of alternative splicing to Cδ). During CSR IgM is replaced by 
one of the six other constant regions which code for the alternate antibody 
isotypes: IgG3, IgG1, IgG2b, IgG2a, IgE and IgA. The mouse constant region 
genes lie on a continuous stretch of chromosome 12. Just upstream of each 
constant region lies a switch region, a highly repetitive 1-5kb DNA sequence 





Adapted from freely licensed media 
 
Figure 1.3. Schematic of class switch recombination. At top, the structure of 
the IgH locus, colored rectangles represent constant region genes and black 
diamonds represent repetitive switch regions. AID introduces DSBs in switch 
regions and the intervening region is excised and circularized. NHEJ repairs 
DSBs, juxtaposing an alternative constant region to the VDJ gene segments. 
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Upon antigen encounter, B cells enter the germinal center and express AID 
(Muramatsu et al., 1999). AID was discovered by a subtractive hybridization 
screen in a B lymphoma cell line, and is required for CSR in mice and humans 
(Muramatsu et al., 2000; Muramatsu et al., 1999). AID deaminates cytidine 
residues on DNA, converting them to uracil (Dickerson et al., 2003; Petersen-
Mahrt et al., 2002; Pham et al., 2003), primarily at WRCY motifs (W=A or T, R=A 
or G, Y=C or T) (Martin et al., 2002). During somatic hypermutation, AID 
introduces U:G mismatches into the immunoglobulin variable regions, which can 
then be processed into an array of mutations to diversify the antigen-binding 
motif (Peled et al., 2008). During CSR (which will be the focus of this section) 
mismatches are processed into switch region DSBs, which are joined with 
deletion of the intervening sequence (Figure 1.3) (Stavnezer et al., 2008). 
 
AID targeting to the switch region. The mechanism by which AID targets switch 
region cytidines for deamination has been long-studied and recently, the 
molecular underpinning has been revealed. CSR was initially associated with 
transcription by the discovery of non-coding transcripts of class switched 
constant region genes in a lymphoma cell line (Stavnezer-Nordgren and Sirlin, 
1986). Later work showed that certain cytokines stimulate germline transcripts 
and CSR. Specifically, TGF-beta induces IgA transcripts and switching to IgA in 
lipopolysaccharide (LPS) stimulated B cell cultures (Lebman et al., 1990). 
Additionally, deletion of the promoters responsible for sterile transcripts abolishes 
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CSR (Jung et al., 1993). Finally, AID activity on a transcribed gene has been 
shown to increase proportionally with transcription (Yoshikawa et al., 2002). 
Switch regions are repeat-rich and significantly enriched in guanine, so the 
formation of secondary structures has been hypothesized to play a role in AID 
targeting. Transcribed G-rich DNA is predisposed to forming stable RNA:DNA 
hybrids in R loops. Indeed, the presence of stable RNA-DNA hybrids (R loops) 
has been shown by bisulphate sequencing and has been detected in vivo (Yu et 
al., 2003). 
 
The R loop as a potential substrate for AID is consistent with AID’s activity on 
ssDNA, which is exposed in the transcription bubble. Both in vivo and in vitro 
assays have demonstrated that ssDNA is a high efficiency substrate for AID, 
while dsDNA is not (Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson et 
al., 2003; Petersen-Mahrt et al., 2002; Pham et al., 2003; Ramiro et al., 2003; 
Sohail et al., 2003). For example, incubation of dsDNA with RNA polymerase in 
an in vitro transcription system with AID resulted in cytidine deamination on the 
non-transcribed strand (Pham et al., 2003). In B cells, AID has been shown to 
interact with PolII, demonstrating a physical interaction with the transcription 
machinery (Nambu et al., 2003; Pavri et al., 2010). Interestingly, AID appears to 
have activity on both the transcribed and non-transcribed DNA strand in SHM 
and CSR, although only the non-template strand is single stranded. AID may 
access ssDNA on the non-template strand by interaction with the ssDNA binding 
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protein Replication protein A (RPA) (Chaudhuri et al., 2004). The exosome 
complex may play a role in facilitating non-template strand access as well (Basu 
et al., 2011). 
 
The distribution of PolII on the IgH locus provides additional insight into the 
mechanism of AID targeting. PolII ChIP experiments showed a high density of 
AID-independent PolII throughout the repetitive switch region, indicative of 
polymerase stalling (Rajagopal et al., 2009). Corroborating this finding, run-on 
analysis (a direct measure of transcription in vivo) also detected stalled 
transcripts in the switch region (Rajagopal et al., 2009). This stalling profile 
matched the hypermutation distribution well; together suggesting that stalling 
might precede and orchestrate AID targeting. Interestingly, G-rich switch region 
repeats appear to directly encourage stalling; in their absence PolII accumulation 
was not observed. Polymerase stalling results in a persistent transcription bubble 
and thereby, the prolonged exposure of ssDNA (Pavri et al., 2010). Given AID’s 
proclivity for deamination of ssDNA, these data provide an attractive framework 
for AID targeting.  Namely, switch regions bear high levels of stalled PolII, which 
exposes ssDNA, a high efficiency substrate for AID. 
 
In 2010, Pavri and collegues performed an shRNA screen for factors that 
abrogate CSR in the CH12 B lymphoma cell line. They identified Suppressor of 
Ty5 Homolog (Spt5), as required for CSR (Pavri et al., 2010). Spt5 is a 
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transcription factor that associates with stalled PolII (Rahl et al., 2010), or PolII 
that accumulates in the promoter-proximal region. They showed that Spt5 directly 
associates with AID, and is required for AID recruitment to the IgH locus. ChIP-
Seq in B cells of Spt5 revealed marked colocalization of Spt5 and PolII, with the 
IgH locus being the greatest area of enrichment for both, genome-wide. 
Additionally, AID ChIP-Seq correlated well with both Spt5 and PollI ChIP-Seqs; 
thousands of loci were found to load AID, and these loci also bore stalled PolII 
and Spt5. The promoter-proximal regions of these genes (an established area of 
stalling) were the primary sites of enrichment. Taken together, these data 
suggest that AID deaminates cytosines on ssDNA exposed by stalled PolII, and 
is targeted by interacting with Spt5. Indeed, the authors showed that Spt5 and 
AID interact in both primary B cell and fibroblasts. To confirm, the authors 
sequenced 10 genes that bore high levels of Spt5 for mutations. Generally, these 
genes suffered mutation, but 10 genes represent a very limited survey. A direct 
genome-wide measure of AID activity would be the ideal comparison, but the 
technology for such an experiment was not available. 
 
U:G mismatches yield switch region DSBs. The U:G mismatch introduced by AID 
may be processed into DSBs. Several experimental approaches have been used 
to demonstrate switch region DSBs during CSR. First, the DNA damage 
response protein NBS1 and the DNA damage induced histone mark γH2AX form 
AID-dependent foci at the IgH locus in stimulated B cells (Petersen et al., 2001). 
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Second, linker-mediated PCR (LM-PCR), a technique to capture and amplify 
genomic DSBs at a particular locus, indicates AID-dependent DSBs at the switch 
regions (Schrader et al., 2005). But, how does a U:G mismatch result in a DSB? 
It has been shown that proteins in the base excision repair pathway (BER) effect 
this conversion. The mismatch is recognized and converted to an abasic site by 
Uracil DNA Glycosylase (UNG1) (Di Noia and Neuberger, 2002; Imai et al., 2003; 
Rada et al., 2002; Schrader et al., 2005). APE endonucleases can recognize this 
abasic lesion and cleave the DNA backbone to generate a single strand nick 
(Guikema et al., 2007). Thereafter, the precise mechanisms are unclear but it is 
thought that staggered nicks are processed into DSBs. The mismatch repair 
pathway, while not strictly required for class switching, may play a role in the 
generation of DSBs (Bardwell et al., 2004; Martin et al., 2003; Martomo et al., 
2004; Schrader et al., 1999). Exo1 may be recruited the mismatch site by the 
MSH2-MSH6 complex, which then performs nucleotide excision followed by 
strand resection (Bardwell et al., 2004; Martomo et al., 2004). It has been 
hypothesized that paired nicks on opposite strands might be simultaneously 
resected thereby generating a DSB. 
 
DSB repair at the switch region. DSBs in the switch region triggers the normal 
DNA damage response. DSBs are recognized by the MRN complex, which is 
followed by activation and accumulation of ATM, a serine/threonine kinase (Falck 
et al., 2005; You et al., 2005). ATM phosphorylates multiple downstream 
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effectors including the histone variant H2AX, converting it to γH2AX (Rogakou et 
al., 1998). γH2AX, in concert with other histone modifications and early DNA 
damage response factors, provides a scaffold for the focus formation of several 
DNA damage response factors such as MDC1 and 53BP1 (Schultz et al., 2000; 
Xie et al., 2007). The presence of these factors at the IgH locus in B cells 
undergoing CSR has been demonstrated by immuno-FISH (Petersen et al., 
2001). The absence of these proteins results in reductions in CSR ranging from 3 
fold, as in the case of ATM (Reina-San-Martin et al., 2004), to complete absence, 
as in the case of 53BP1 (Ward et al., 2004). 
 
Sequencing of switch region junctions in class switched B cells shows that the 
majority do not contain significant microhomology (Yan et al., 2007), suggesting 
that the NHEJ pathway carries out the deletional recombination reaction. In mice 
with preassembled heavy and light chains that bear conditional deletion of the 
NHEJ factors XRCC4 or Lig4, CSR still occurs at 50% of wild type levels (Yan et 
al., 2007). Switch junctions in this system showed microhomology utilization, 
indicating that in the absence of NHEJ alt-NHEJ can contribute to efficient CSR. 
Similar results were obtained in a mouse lacking Ku70 and Lig4 (Boboila et al., 
2010b). Thus, joining of switch region DSBs usually occurs by NHEJ, but in the 
absence of NHEJ pathway components, alt-NHEJ may perform the repair. 
 
In contrast, the absence of 53BP1 results in complete abrogation of class 
 47 
switching (Manis et al., 2004; Ward et al., 2004). Instead of joining DSBs in 
disparate switch regions, B cells lacking 53BP1 rejoin DSBs, producing 
intraswitch deletions. It has been hypothesized that this may be the result of DNA 
hypomobility in the absence of 53BP1. 53BP1 deficient cells show decreased 
movement of uncapped telomeres and B cells from 53BP1-/- mice fail to perform 
efficient V(D)J recombination to distal gene segments (Difilippantonio et al., 
2008; Dimitrova et al., 2008). Alternatively, 53BP1 has been shown to protect 
ends from resection; in its absence, ssDNA is exposed and available for 
microhomology utilization in joining (Bothmer et al., 2011; Bothmer et al., 2010). 
Thus, it is hypothesized that in the absence of 53BP1 switch region DSBs are 




AID Mediates Mutations and Translocations in Non-Ig Genes 
 
AID generates physiological U:G mismatches in the switch region and variable 
regions to generate downstream DSBs and mutations, respectively. In the current 
model, AID is targeted to these regions by a physical interaction with Spt5, a PolII 
stalling factor. However, AID has been shown to mutate, translocate, and 
introduce DSBs in non-Ig genes. In fact, the study of AID activity at non-
immunoglobulin loci has been instrumental in deciphering AID’s targeting 
mechanism. Several non-Ig targets of AID have been implicated in 
lymphomagenesis, thereby associating AID with genomic instability in these 
tumors. 
 
AID introduces mutations in non-Ig genes. Initial studies indicated that AID 
activity was associated with switch region transcription. Moreover, Ig genes could 
still be mutated when replaced with another promoter (Betz et al., 1994; Tumas-
Brundage and Manser, 1997), and non-Ig sequences were mutated when in the 
context of the Ig locus. Therefore, it stood to reason that other transcribed genes 
might suffer AID mediated mutation. A first study isolated memory and naïve B 
cells from the peripheral blood of healthy donors and sequenced a select panel of 
genes. They found that BCL-6, a gene expressed in germinal center B cells and 
reported to carry mutations in non-Hodgkin’s lymphoma, was significantly 
mutated (Shen et al., 1998). Importantly, the mutation spectrum was similar to 
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that found in Ig genes. A subsequent study had similar findings, but also reported 
that BCL-6 sequencing from B cell tumors showed that only those cancers with a 
germinal center or post-germinal center phenotype carried mutations 
(Pasqualucci et al., 1998). Additionally, CD95 was shown to bear a similar 
mutation spectrum in the GC B cells of healthy donors (Muschen et al., 2000). 
Later work expanded the roster of expressed, mutated non-Ig genes to include 
Pim1, c-myc, Pax5, CD79a and CD79b (Gordon et al., 2003; Pasqualucci et al., 
2001). Importantly, mutation at these loci displayed a similar profile to variable 
region mutations but at a much lower frequency; a preference for transitions over 
transversions and specific targeting to WRCY motifs. These papers suggested 
that AID might target non-Ig genes for mutation.  
 
A broader study of AID dependent mutation in germinal center B cells suggested 
that AID might very widely mutate transcribed genes. Liu and colleagues isolated 
germinal center B cells from AID deficient and wild-type mouse peyer’s patches, 
then sequenced 118 genes, in a region 1.5kb downstream from the transcription 
start site based on their expression in the germinal center. While mutation 
frequencies were about 100 times lower than immunoglobulin mutation rates, 
25% of the genes examined bore significant AID dependent mutations (Liu et al., 
2008). Consistent with previous studies, BCL6 was the most highly mutated gene 
in the experimental set. Interestingly, when the same genes were sequenced in 
germinal center B cells from mice lacking UNG and MSH2, several genes 
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including the c-myc proto-oncogene, appeared to have increased mutations 
rates. This suggested that some genes targeted by AID might undergo error-free 
repair by the base excision repair and mismatch repair pathways.  
 
This study was the most comprehensive analysis of non-Ig AID targeting at the 
time, and surely demonstrated that AID triggers mutation at several locations 
throughout the genome. However, low-throughput sequencing is a relatively 
cumbersome technique, prohibiting its application in a truly comprehensive study. 
Indeed, these experiments delivered a limited picture of AID’s role in genomic 
instability. First, only genes were examined for mutation; this excluded the 
possibility of discovering AID’s role in targeting non-genic regions, should it have 
one. Second, from thousands of potentially mutated genes only a small percent 
were examined (118 of ~25,000 or 0.5%), while these result were generalized to 
conclude that 25% of all genes are mutated, it was not a true measure of AID 
promiscuity. Third, the selection criteria for genes required that they be in the top 
decile of microarray expression values; as such, the effects of transcription on 
non-Ig AID-dependent mutations could not be effectively assessed. Fourth, they 
only sequenced a 1 kb region of each gene in the same location – 1.5 kb 
downstream from the transcription start site. Whether this is the primary site of 
AID targeting in the gene body was unexamined. Finally, while mutations may be 
a proxy for DSBs, especially in the absence of UNG, DSBs and subsequent 
translocation were not directly measured. In fact, no system to perform an 
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unbiased, large-scale analysis of AID dependent translocations has yet been be 
devised. 
 
Expanding on this work, a recent genome-wide study revealed the full spectrum 
of potential AID targets. Yamane and colleagues performed AID-ChIP followed 
by deep sequencing and showed that AID is associated with almost 6,000 genes 
in activated B cells. This confirmed the assertion from Liu and colleagues that 
AID might associate with 25% of all genes. As expected, the IgH locus loaded the 
greatest quantity of AID, while genes previously shown to be mutated by AID or 
translocated in mature B cell lymphomas appeared throughout the list. For 
example, mir-142 (a translocation partner of c-myc and mutation target of AID 
(Gauwerky et al., 1989; Robbiani et al., 2009)) was among the 15 genes with the 
greatest AID levels. Importantly, the presence of AID as determined by ChIP-Seq 
was predictive of AID-mediated mutation, suggesting that AID both binds and 
mutates promiscuously (Yamane et al., 2011).  
 
When compared to histone modification and PolII ChIP-Seq landscapes, several 
trends emerged. AID was shown to primarily associate with transcribed genes as 
determined by mRNA-Seq, and to associate with open chromatin as determined 
by the histone modification H3K4 trimethylation. Within the gene body, AID 
bound predominantly at the promoter proximal sequence, and colocalized with 
putative sites of RNA PolII accumulation and stalling. This meshed well with 
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previous data suggesting that AID targeting depends on PolII stalling and ssDNA 
availability (Pavri et al., 2010; Rajagopal et al., 2009). However, this study was 
marked by some limitations. First, AID association is a substitute evaluation for 
AID activity, so while AID ChIP-Seq may define sites of AID association it is not a 
direct measure of activity. Second, after surveying 13 AID associated genes for 
mutations, it was concluded that AID ChIP-Seq is a good proxy for AID activity, 
but this is a relatively small-scale analsis. Third, the authors conclude that AID 
association correlates well with AID-mediated mutation, but the question of AID 
mediated translocations and DSBs was left unaddressed. 
 
AID-mediated translocations. AID is also responsible for initiating translocations, 
events commonly observed in mature B cell lymphomas. For instance, formation 
of the c-myc/IgH translocation (a hallmark of Burkitt’s lymphoma) in the IL-6 
induced plasmacytoma lymphoma model, requires the presence of AID (Ramiro 
et al., 2004). Moreover, the same translocation occurs in primary B cell in culture 
within hours of AID expression, and only in the presence of UNG (Ramiro et al., 
2006). The requirement for UNG indicates that the conversion of U:G 
mismatches to DSBs is required for translocation, and strongly implicates AID in 
directly initiating the DSB.  
 
Translocations require paired DSBs (Richardson and Jasin, 2000), and while AID 
had been conclusively shown to initiate DSBs in IgH, the etiology of the DSB in c-
 53 
myc was unclear. Fragile DNA elements prone to form non-B-DNA 
configurations, including Z-DNA, triple-helical H-DNA, and G-quadruplex DNA 
have been proposed to account for breaks in c-myc (Liu and Levens, 2006; 
Marcu et al., 1992; Wierstra and Alves, 2008). Recently, direct evidence for AID 
generating the DSBs in c-myc came from genetic experiments using the site-
specific yeast meganuclease I-SceI. In mice bearing I-SceI sites in both IgH and 
c-myc I-SceI is sufficient to produce c-myc/IgH translocations, and when I-SceI is 
only present at IgH, I-SceI and AID together produce c-myc/IgH translocations. 
However, in the absence of AID, I-SceI-mediated DSBs in IgH did not generate c-
myc/IgH translocations (Robbiani et al., 2008). Thus, AID is responsible for the 
breaks in c-myc that partner with IgH to form the c-myc/IgH translocation. 
 
AID’s ability to introduce DSBs at IgH and non-Ig loci such as c-myc may play a 
role in mature B cell lymphomagenesis in vivo. In humans, AID is expressed in 
mature B cells lymphomas that carry translocations to IgH. For example, AID is 
expressed in activated B cell-like diffuse large B cell lymphoma (ABC-DLBCL) 
(Lenz et al., 2007) and, ABC-DLBCL has a high frequency of illegitimate switch 
region recombinations and deletions, as well as translocations involving IgH 
(Lenz et al., 2007) to genes targeted for mutation by AID, such as c-myc and 
BCL6. These findings associate AID with lymphomagenesis, but a mouse model 
finally proved that AID causes mature B cell lymphomas, 
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Several transgenic mice constitutively over-expressing AID have been generated 
and many of these mice develop cancer. However, the tumors are not of B cell 
origin, instead they are epithelial tumors and T cell lymphomas (Muto et al., 2006; 
Okazaki et al., 2003; Shen et al., 2008). These tumors carried mutations in 
oncogenes, but did not bear any translocations (Okazaki et al., 2003). 
Additionally, in conflict with the IL-6 induced plasmacytoma mouse (which bore 
tumors only in the presence of AID), mice with a B cell specific AID transgene did 
not succumb to any tumors (Muto et al., 2006). In 2009, Robbiani and colleagues 
published the first direct evidence that AID contributes to lymphomagenesis in 
vivo. p53-/- mice overexpressing AID from a transgene in B cells by virtue of V 
kappa promoter succumbed quickly to mature B cell lymphomas (Robbiani et al., 
2009). This was in contrast to the control group of p53-/- mice, which perished 
from T cell lymphomas and sarcomas. Important, B cell lymphomas in these mice 
carried clonal reciprocal translocations, including the c-myc/IgH translocation 
observed in Burkitt’s lymphoma. This mouse model also yielded tumors bearing a 
clonal translocation between c-myc and mir-142. The c-myc/mir-142 translocation 
juxtaposes the c-myc coding region to the mir-142 regulatory elements, thereby 
dysregulating c-myc expression. Sequencing of the mir-142 locus from germinal 
center B cells in WT and AID-/- mice revealed that mir-142 is a bona fide target of 
AID. This discovery provided further evidence for AID’s role in lymphomagenesis 
in humans; the c-myc/mir142 translocation has been reported in a human 
aggressive B cell leukemia (Gauwerky et al., 1989).  
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These studies nicely show that AID is capable of initiating DSBs and 
translocations. However, to date c-myc and mir142 are the only genes 
conclusively shown to suffer AID dependent translocation. B cells overexpressing 
AID harbor high levels of translocations and chromosome breaks (Robbiani et al., 
2009). But, the entire array of genes susceptible to DSBs by AID is unknown 
because a method for high-resolution unbiased mapping of DSBs or their 




CHAPTER 2:  
Translocation Capture Sequencing 
 
Recent deep-sequencing studies have revealed hundreds of genomic 
rearrangements in human cancers (Campbell et al., 2008; Pleasance et al., 
2010a; Pleasance et al., 2010b; Stephens et al., 2009). These studies have shed 
some light on the nature and extent of genomic abnormalities. However, 
rearrangements from tumors may be highly selected, and cancer cells might 
have altered DNA repair pathways that give rise to a different rearrangement 
profile. Thus, the physiologic constraints that govern the genesis of these events 
remain unclear because methods for mapping chromosomal translocations in 
primary cells do not yet exist. Here, we sought to develop a genome-wide 
strategy to document chromosomal rearrangements in short-term cultures of 
primary cells. 
 
In our system, DSBs are induced at the c-myc (chromosome 15) or IgH 
(chromosome 12) loci, which were engineered to harbor the I-SceI 
meganuclease target site (Robbiani et al., 2008) (c-mycI-SceI/I-SceI or IgHI-SceI/I-SceI B 
cells respectively, hereafter referred to as MycI and IgHI) (Figure 2.1). I-SceI, an 
intron encoded endonuclease present in the mitochondria of Saccharomyces 
cerevisiae, recognizes an 18 base pair sequence absent from the mouse 
genome. The I-SceI break system was first developed in mammalian cells to 
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examine DSB resolution (Rouet et al., 1994). It has since been widely used to 
study many aspects of DSB repair including DSB end processing, chromosomal 
translocation, pathway selection, and to perform gene targeting (Bothmer et al., 
2010; Brunet et al., 2009; Windbichler et al., 2007). Here, the unique break at I-
SceI sites serves as bait for other endogenous breaks in the cell, thereby 













Figure 2.1. Schematic of loci containing I-SceI sites. The IgH locus of IgHI B 
cells is shown below, while the c-myc locus from MycI B cells is shown above.  
Each is displayed with the site-specific primers used for TC-seq and their 
approximate distance from the I-SceI site. Nested primers were placed at least 
150 bp from the I-SceI site to allow for capture of events generated from 
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To generate genomic DNA bearing rearrangements to I-SceI sites, mouse 
splenic B cells were isolated by immunomagnetic depletion with CD43 beads and 
stimulated to undergo isotype switching in cultures with LPS and IL-4. The CD43 
antigen is expressed on most T cells, NK cells, granulocytes, monocytes, and 
macrophages, on hematopoietic stem cells, and platelets. Among B cells, CD43 
is expressed on activated B cells and plasma cells but not on resting B cells 
(naive B cells) (from Miltenyi Biotech). On culture days one and two activated B 
cells were infected with retroviruses to express I-SceI (with mCherry by virtue of 
an embedded IRES element), and in some cases AID (with GFP by virtue of an 
embedded IRES element). On day 4 singly infected cells were harvested for 
genomic DNA while doubly infected cultures were sorted for double positive cells 













Figure 2.2. Schematic of concept for rearrangement generation. B cells 
bearing I-SceI sites are isolated and infected with retroviruses to express I-SceI 
endonuclease with or without AID. I-SceI cleaves the target sequence, which may 
then join to endogenous DSBs to generate chromosomal rearrangements with 
one known partner. Alternatively, the I-SceI induced break might religate and 








We sought a method to isolate and sequence rearranged I-SceI sites. Of course, 
classical PCR could not be utilized; rearrangements to the I-SceI site only contain 
one known partner sequence. Essentially, this task requires a mechanism for 
amplifying a genomic region using only one site-specific primer. A solution was 
developed in 1989 to perform in vivo footprinting of enhancers and methylation 
analysis (Mueller and Wold, 1989; Pfeifer et al., 1989). By ligating DNA to double 
stranded linkers then using primers that anneal to the sequence of interest and 
the linker, one can perform single-sided PCR (dubbed ligation-mediated PCR or 
LM-PCR). Since then, this technique has been used in various applications 
including the investigation of genetically programmed DSBs in lymphocytes and 
HIV integration site mapping (Papavasiliou and Schatz, 2000; Schroder et al., 
2002; Zhu and Roth, 1995). We designed linkers to allow for high-fidelity PCR 
with low background by including the following features.  
 
1) Strand asymmetry; to allow for novel sequence generation in the case of 
site-specific primer extension (Figure 2.3). 
2) Thymine tail; to prevent linker-linker dimer formation, and to accommodate 
genomic DNA fragment adenine tailing so that intermolecular ligation 
events do not occur (Figure 2.3). 
3) Dideoxycytosine block; to prevent double stranded linker generation in the 
absence of site-specific primer extension (Figure 2.3) 
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4) AscI cleavage site; to remove linkers prior to deep-sequencing. 
Additionally, AscI cleavage will leave an 8 nucleotide barcode on 











Figure 2.3. Structure of LM-PCR linker. The double stranded asymmetric linker 
(dsaLinker) for LM-PCR contains a T-tail, 5’ overhang, AscI site and a 












First, genomic DNA was sonicated to a mean size of 800 bp, blunted, A-tailed 
and ligated to dsaLinkers. Then, purified I-SceI enzyme was applied to eliminate 
unrearranged target loci. (Figure 2.4A). Each sample was then divided into 2 
equal parts, for TC-Seq with either forward or reverse primers. Forward and 
reverse preparations were processed separately for the entire protocol. DNA was 
subjected to single-primer PCR with biotinylated site-specific primers. This step 
generates a complete double stranded linker on genomic DNA fragments 
containing the I-SceI adjacent sequence (Figure 2.4B). 
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Figure 2.4. Translocation sequencing schematic I. (A) To prepare genomic 
DNA for TC-Seq it is sonicated, blunted, A-tailed, ligated to dsaLinkers and cut 
with I-SceI. (B) Single-primer PCR. Prepared genomic DNA fragments were 
subjected to 15 cycles of PCR with a single biotinylated primer annealing either 
















Next, PCR reactions were spiked with primer that anneals to the newly generated 
linker sequence. Higher molecular weight products were isolated from the 
reaction by agarose gel electrophoresis followed by streptavidin bead purification. 
A semi-nested PCR was performed (with primers pLinker and pIgHF2, pIgHR2, 
pMycF2 or pMycR2) (Figure 2.1), and higher molecular weight products were 
isolated by agarose gel electrophoresis. Finally, linkers were removed by AscI 
digestion and fragments were assembled into an Illumina library for Paired End 
deep-sequencing. 36x36 or 54x54 nucleotide sequencing was performed on an 
Illumina GAII (Figure 2.5) (See methods for an in-depth TC-Seq protocol 















Figure 2.5. Translocation sequencing schematic II. Following LM-PCR, 
products were isolated by strepavidin coated magnetic bead purification and 
subjected to semi-nested LM-PCR. Linkers were cleaved off fragments by 
digestion with the restriction endonuclease AscI then were processed into paired-














TC-Seq libraries were generated from 50 million B cells each. Experiments were 
performed in duplicate (biological replicates) for a total of 100 million B cells 
assayed per condition. To determine AID’s contribution to the genomic 
rearrangement landscape TC-Seq libraries to IgH and c-myc were assembled 
from AID deficient, AID sufficient and AID over-expressing (by retroviral infection) 
B cells (Table 2.1). Illumina sequencing runs were repeated on some samples 
(technical replicates) to increase depth and ensure saturation. 
 
Next, sequencing data were mined for useful reads. Each end of the paired-end 
sequences was matched against the relevant bait primer (IgHF2, IgHR2, MycF2 
or MycR2) plus genomic sequences allowing up to two mismatches with the 
bowtie short read aligner. For read pairs longer than 2 x 36 nts, 10 nts were 
trimmed off the 3’ end of each read. Each read pair with a single match to one of 
the site-specific primers was then checked for a perfect match to the linker 
barcode on the second arm. After AscI cleavage, eight nucleotides remain ligated 
to the genomic DNA, this was termed the “barcode” and it indicates linker-specific 
amplification. If the barcode was present, this arm was designated a target arm, 
linker sequence was trimmed, and the remainder was aligned against the mouse 
genome (NCBI 37/mm9) with bowtie allowing up to 2 mismatches and requiring 
unique alignments in the best alignment stratum (command line options: -v2 --all 
--best --strata -m1). Exactly identical alignments (same position, same strand) 
were combined into a single putative rearrangement event, events supported by 
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a single alignment were not considered in any analyses. Since TC-Seq involves 
multiple rounds of PCR, it is unlikely that individual reads represent actual 
biological events. We also removed reads closer than 1 kb to their respective 
bait; these alignments represent rejoining of the I-SceI break, uncut, or 
unrearranged loci. Rearrangement positions are given as the position of the 5’ 
end of the read in the alignment. It should be noted that these reads are 
displaced from the actual rearrangement breakpoints. Based on the distance of 
the primers from the I-SceI site and agarose gel size selection, the average 
displacement is expected to be ~250 bp. For all analyses, data from technical 







Table 2.1. Data quantity per experiment. Bait – the locus containing I-SceI for 
each experiment. AID – the status of activation induced cytidine deaminase 
(wt=wild type, ko=knockout, rv=retroviral over-expression). Replicate – indicates 
which biological replicate the data set represents, identical letters indicate 
technical replicates of the same experiment, biological replicates are indicated by 
different letters. Sequenced pairs – total number of paired reads obtained. Valid 
pairs – total number of paired reads containing a matched linker and site-specific 
primer. Left – number of valid aligned reads paired with a forward primer. Right – 
number of valid aligned reads paired with a reverse primer. Total – total number 
of valid, aligned reads paired with a site-specific primer, for tabulated rows (gray 
shading) this value is the sum of the replicate experiments. Rearrangements [>1 
kb from bait; >= 2 alignments] – total number of valid, aligned, unique reads 
represented by more than 1 read instance and lying greater than 1kb from the 
associated site-specific primer, for tabulated rows (gray shading) this value is the 








Table 2.1. Data quantity per experiment. 
bait AID Repli-cate 
sequenced 




bait; >= 2 
alignments] 
cMyc ko A 37,496,617 16,759,723  4,071,732 6,600,751 10,672,483 16,172 
cMyc ko B 31,561,878 16,112,165  5,763,288 5,113,161 10,876,449 14,816 
    A+B           28,548 
          
cMyc rv A 42,942,899 13,132,287  2,610,943 458,513 3,069,456 25,653 
cMyc rv A 39,981,085 12,332,625  2,979,621 513,095 3,492,716 26,465 
    A           6,562,172 39,789 
cMyc rv B 39,119,951 15,277,084  4,997,453 1,563,572 6,561,025 27,001 
    A+B         13,123,197 63,772 
          
IgH rv A 35,443,959 11,779,691  1,448,672 2,315,695 3,764,367 35,167 
IgH rv A 10,860,307 2,797,362  212,458 970,485 1,182,943 21,677 
IgH rv A 16,897,163 4,582,262  386,947 1,531,206 1,918,153 26,455 
    A           6,865,463 43,315 
IgH rv B 5,586,756 1,820,820  247,532 226,915 474,447 19,720 
    A+B         7,339,910 51,312 
IgH ko A 42,015,461 9,945,416  890,202 4,233,574 5,123,776 67,156 
IgH ko B 12,289,033 2,723,023  701,452 334,221 1,035,673 1,247 
    A+B             
IgH wt A 40,136,125 20,570,387  5,169,695 2,536,311 7,706,006 31,601 
IgH wt B 25,885,221 8,005,979  1,507,154 1,665,017 3,172,171 14,104 








CHAPTER 3:  
AID-Independent Rearrangements In 
Activated B Cells 
 
In the absence of AID, DSBs arise as by-products of normal cellular metabolism 
including transcription, oxidative stress and DNA replication (Branzei and Foiani, 
2010). To examine the distribution of AID-independent DSBs that lead to 
rearrangements we examined rearrangements to I-SceI sites in c-myc, in the 
absence of AID.  Consistent with a global distribution of DSBs, we mapped 
28,548 unique rearrangements between the I-SceI site and every chromosome in 




Figure 3.1. Genomewide view of rearrangements to MycI in AID-/- B cells. 
Rearrangements were mapped according to genomic position and displayed by 
the Circos circular visualization software package (http://circos.ca). Each line 
originating from c-myc on chromosome 15 represents a single rearrangement 
event. The red arrow indicates the I-SceI site embedded in c-myc. 
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To determine whether there is a genome-wide bias for rearrangement, these 
events were characterized based on location, transcriptional status and histone 
modification of the locus. First, we examined chromosomal location and found a 
marked enrichment of intra-chromosomal rearrangements on chromosome 15, 
with approximately 125 events per mappable megabase (11,066 
rearrangements), or ~40% of all events genomewide (Figure 3.2). In contrast, 
translocations between MycI and other chromosomes were evenly distributed 




Figure 3.2. Rearrangements to each chromosome in MycIAID-/- B cells. 
Rearrangement partners to I-SceI sites in c-myc were binned based on 
chromosome, each bin was divided by the number of mappable megabases of 
sequence for that chromosome in the mm9 genome build. 
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Notably, 86.7% (9,591 of 11,066) of all intra-chromosomal rearrangements were 
localized within a 350 kb domain surrounding the I-SceI site (from -50 kb to +300 
kb; Figure 3.3). This is consistent with the observation that 92% of intra-
chromosomal rearrangements in the breast cancer genome involve aberrant 
joining of DSBs within 2 Mb of each other (Stephens et al., 2009), and that 87% 
of RAG-mediated intra-chromosomal rearrangements in Abl-transformed pre-B 
cells lie within 200 kb of a recombination substrate (Mahowald et al., 2009). The 
asymmetrical distribution of events in the direction of c-myc transcription and the 
adjacent Pvt1 gene is also consistent with the idea that gene expression 
facilitates rearrangement (Thomas and Rothstein, 1989). I-SceI-proximal events 
may be the result of either resection and rejoining of I-SceI breaks, bona fide 
rearrangements between I-SceI and random DSBs, or a combination of DNA end 
resection and balanced translocations. Regardless of the precise molecular 
mechanism, the abundance of these events reveals a strong preference for 
DSBs to be resolved by ligation to a proximal sequence, a DNA repair strategy 








Figure 3.3. Profile of rearrangements around the c-myc I-SceI site. Local 
rearrangements in MycI were mapped in 5 kb bins around the I-SceI site.  Black 
dots represent values at individual bins, the red line represents a smoothed 
moving average of bin contents. Data were plotted on a logarithmic scale. Below, 
schematic of the c-myc locus containing the position of the adjacent gene, pvt1. 
Arrows indicate the direction of transcription. 
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Recent cancer genome sequencing experiments uncovered a modest but highly 
significant preference for cancer-associated rearrangements to occur in genes, 
which compose only 41% of the human genome. For example, in 24 sequenced 
breast cancer genomes, 50% of all rearrangements involved genes (Stephens et 
al., 2009). Whether this bias resulted from selection or some inherent feature of 
DSB formation and repair specific to cancer cells could not be determined. To 
ascertain whether a similar bias is seen in primary cells in short term cultures, 
AID-independent rearrangements in MycIAID-/- B lymphocytes (excluding 1 Mb of 
DNA around the I-SceI site) were classified as genic or intergenic. Local events 
were omitted from the analysis because of the observed bias for events around 
the break. Consistent with the human tumor studies, 51% (9,677 of 19,246) of the 
events were associated with genes (Figure 3.4A). Because only 40% of the 
mouse genome is genic, this represents a small (1.25-fold) but significant 
difference (permutation test P < 0.001) relative to intergenic regions.  
 
Next, we performed a composite density analysis of rearrangements to genes 
and intergenic regions. In this approach events are mapped along the gene body 
or regions between genes but, instead of mapping by nucleotide position they are 
mapped according to distance from the transcription start site as a percent of the 
entire locus body. For example, a translocation that maps to base 250 of a 1000 
bp gene would be given the value of 25%. Finally, all genes and intergenic 
regions are combined to generate a merged graph of reads along all gene bodies 
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and intergenic spans. Using this approach we find that genic rearrangements 
were particularly enriched at transcription start sites (TSS) (Figure 3.4B). 
Importantly, there appears to be no enrichment at any length along the composite 
intergenic region, indication that the TSS is indeed unique in its enrichment.  
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Figure 3.4. Rearrangements to genic and intergenic regions.  
(A) Rearrangements, excluding the 1 Mb around I-SceI, were categorized as 
genic or intergenic for each sample.  (B) Composite density profile of genomic 
rearrangements from MycI to genes (red line) and intergenic (blue line) regions. 
TSS = transcription start site, TTS = transcription termination site. 
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Next, we asked whether transcriptional activity is a determinant of 
rearrangement. mRNA-Seq data from LPS and IL-4 activated B cells was divided 
into quintiles of expression and the number of rearrangements to each quintile 
was tabulated (Yamane et al., 2011). We then performed 1000 computational 
Monte Carlo experiments to determine the expected value in each transcription 
quintile assuming a random distribution along the genome, using their average as 
an expected frequency. Finally, we calculated relative frequency in each quintile 
(fe) – this number indicates the percent divergence of the observed value from 
the expected. Consistent with the preference for genic rearrangements, there 
was a bias to transcribed genes. Fewer rearrangements than expected occurred 
at silent (fe = 0.74, P < 0.001) and trace (fe = 0.95, P < 0.001) transcribed genes, 
while more than expected occurred at low (fe = 1.08 P < 0.001), medium (fe = 
1.13, P < 0.001), and highly (fe = 1.14, P < 0.001) transcribed genes (Figures 







Figure 3.5. Rearrangements in transcription level gene groups. (A) Genes 
were divided into silent (0 FPKM (fragments per kilobase of exon per million 
fragments mapped)) and expressed genes based on mRNA-Seq (Yamane et al., 
2011). The expressed group showed a bimodal distribution and was subdivided 
into trace expressed genes (<= 4.04 FPKM) and more highly expressed genes 
using a normal mixture model. The higher group was divided again into tertiles 
(low > 4.04 FPKM; medium > 23.5 FPKM; high > 65 FPKM). (B) Relative 
frequency (fe) of rearrangements in genes that are either silent or display trace, 
low, medium or high levels of transcription in activated B cells as determined by 
RNA-Seq. Dashed line indicates the expected rearrangement frequency based 
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To confirm a bias for transcription and open chromatin, we categorized genes as 
either bearing or lacking rearrangements. Next, we asked whether genes in these 
two categories were overrepresented or underrepresented in the population of 
genes that bear activating histone marks and PolII as determined from ChIP-Seq 
on these entities in LPS and IL-4 activated B cells (Yamane et al., 2011). We find 
that rearrangements occur more frequently than expected (in a random 
distribution model) to genes bearing PolII and the activating histone marks H3K4 
trimethylation, H3 acetylation, and H3K36 trimethylation (P < 0.001 for all, Figure 
3.6). Similarly, rearrangements occur less frequently than expected to genes that 
do not load PolII or carry activating histone marks. Thus, there is a propensity for 
a DSB to recombine with gene rich regions of the genome and more specifically 







Figure 3.6. Rearrangements in activating histone mark- and PolII-
associated gene groups. Relative frequency of rearrangements in PolII, H3K4 
trimethylation, H3 acetylation and H3K36 trimethylation-associated gene groups 
(Yamane et al., 2011). Dashed line indicates expected frequency based on a 
random model. P < 0.001 for all samples (permutation test). 
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CHAPTER 4:  
Rearrangements to c-myc and IgH in the 
Presence of AID 
 
Processing of AID induced U:G mismatches can result in DSBs in Ig and non-Ig 
genes such as c-myc (Robbiani et al., 2008). To determine whether AID-
mediated DSBs can be captured by TC-Seq we examined the IgH and c-myc loci 
in B cells expressing retrovirally encoded AID (IgHIAIDRV or MycIAIDRV). IgHI B 
cells expressing both I-SceI and AID showed extensive AID-dependent 
rearrangement between the I-SceI site and downstream switch (S) regions 
(Figure 4.1). The frequency of rearrangements resembled the pattern of AID-
mediated CSR in LPS+IL-4 cultures (e.g. IgG1>>IgG3>IgE), with 18,686 mapping 
to Sγ1, 3,192 to Sγ3, and 1,433 to Sε (Table 4.1). Notably, rearrangements 
mapped preferentially to the switch regions of the immunoglobulin constant 









Figure 4.1. Rearrangements from IgHI to downstream switch regions. 
Rearrangements per kb to I-SceI sites (indicated with an asterisk) in IgH in AID-/- 
(top panel) or AIDRV cells (bottom panel). White boxes in the schematics below 
























114668744 8,475 7,849 5 3,463 
Ig gamma3 
chr12:114594089-
114606686 3,192 4,682 2 253 
Ig gamma1 
chr12:114563338-
114582604 18,686 11,723 0 2,209 
Ig gamma2b 
chr12:114542220-
114557966 284 513 0 19 
Ig gamma2a 
chr12:114525733-
114535551 61 240 0 4 
Ig epsilon 
chr12:114507208-
114518138 1,433 372 1 14 
Ig alpha 
chr12:114496093-
114499984 10 5 0 1 
c-myc 
chr15:61814486-
61825559 45 3 7,386 5,404 
 
Table 4.1. Rearrangement abundance in specific loci. Total rearrangements 
to immunoglobulin constant domains (switch + constant) and c-myc. 100 million 
B cells were used per experiment. 
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Furthermore, TC-Seq detected translocations between c-myc and IgH, and these 
were entirely dependent on AID (Figures 4.2 and Table 4.1). In two biological 
replicate samples totaling 100 million B cells, we observed 45 translocations from 
IgHI to c-myc (the I-SceI DSB was in IgH), and 5,925 from MycI to IgH (the I-SceI 
DSB was in c-myc) (Table 4.1). Additionally, TC-Seq tags mapping to c-myc from 
IgHI correlate well with c-myc/IgH translocation breakpoints sequenced from 
primary B cells (Figure 4.2) (Robbiani et al., 2008). This suggests that TC-Seq 
reads are an accurate proxy for breakpoints. Furthermore, the data corroborate 
previous findings showing that AID induced breaks at c-myc are rate limiting for 
c-myc/IgH translocations (Robbiani et al., 2008) and suggest that AID-dependent 
IgH breaks are two orders of magnitude more frequent than those at c-myc. We 
conclude that TC-Seq captures rearrangements and translocations between 















Figure 4.2. Screenshots of c-myc/IgH translocations. Rearrangements per kb 
to I-SceI sites in c-myc in AID-/- or AIDRV cells (top panel). White boxes in the 
schematics below each graph represent Ig switch domains while black boxes 
depict constant regions. Translocations per 100 bp from IgHI to c-myc in AID-/- or 
AIDRV cells (bottom panel). Green arrows indicate c-myc/IgH translocation 





As was the case for AID deficient samples, MycIAIDRV and IgHIAIDRV libraries 
were enriched in intra-chromosomal rearrangements: 17% (10,633 of 63,772 
total events) for MycI and 70% (36,019 of 51,312) for IgHI (Figure 4.3A and 4.3B). 
The latter likely had more rearrangements on chromosome 12 due to the activity 
of AID at the IgH locus (Figure 4.3).  
 
 
A            B 
 
 
Figure 4.3 Chromosomal distribution of rearrangements in AID-sufficient 
MycI and IgHI B cell genomes. (A) Bar graph displaying total rearrangements 
per mappable megabase per chromosome in MycIAIDRV and (B) IgHIAIDRV B 




Expression of AID did not alter the distribution of events around MycI, with 72.5% 
(7,707 of 10,633) mapping within -50 kb to 300 kb of the break (Figure 4.4). A 
notable exception was an additional cluster of rearrangements associated with 
Pvt1 exon 5 (Figure 4.4). These events coincided precisely with documented 
chromosomal translocations isolated from AID sufficient mouse plasmacytomas 





Figure 4.4. Profile of local rearrangements in MycI B lymphocytes, in the 
presence and absence of AID. Rearrangements per 5 kb around MycI, I-SceI 
site indicated with an asterisk. Distribution in the absence (gray line) or presence 
(red line) of AID. Green arrows indicate plasmacytoma translocation breakpoints. 
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In agreement with the MycIAID-/- samples, translocations between IgHI or MycI 
and other chromosomes were evenly distributed throughout the genome, except 
for the MycI capture sample, which displayed a marked bias for chromosome 12 
due to creation of DSBs at the IgH locus by AID (Figure 4.1). Similar to MycIAID-/- 
samples, rearrangements in both cases were more likely to occur in regions that 
are genic, transcriptionally active, recruiting PolII, and associated with activating 
histone marks (Figures 4.5 and 4.6A). Furthermore, intragenic rearrangements 







Figure 4.5 Rearrangements to transcription-level gene groups in AIDRV B 
cells. Relative frequency of rearrangements in transcription-level gene groups to 
I-SceI sites in AID sufficient B cells. IgHIAIDRV is on the left while MycIAIDRV is on 
the right. Dashed line indicates expected frequency based on a random model. 
Asterisks highlight values with a P < 0.001 (permutation test).  
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Figure 4.6. Rearrangements to histone and PolII-associated gene groups 
and gene body distribution in AID sufficient cells. (A) Relative frequency of 
rearrangements in PolII-associated or activating histone mark-associated gene 
groups (Yamane et al., 2011). IgHI (left) or MycI (right) AIDRV captures. Dashed 
line indicates expected frequency based on a random model. P < 0.001 for all 
(permutation test). (B) Composite density profile of rearrangements, genic (red) 
and intergenic (blue) regions in IgHI (upper) or MycI (lower) AIDRV captures. 
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In contrast to recent studies that used Nbs1 as an indirect marker of AID 
mediated damage (Staszewski et al., 2011), we found little or no difference in 
rearrangements to genomic repeats in the presence of AID (Table 4.2). Thus, 
AID does not dramatically alter the general profile of rearrangements.  
 









CA 507 0.0271 1528 0.028 0.5361 
LINE 1084 0.0579 3137 0.0574 0.197 
SINE 862 0.0461 2645 0.0484 0.7991 
Others 2610 0.1395 7048 0.1291 0.0003 
Total 18707  54605   
 
Table 4.2. Rearrangements in intergenic repeats in MycIAIDRV and MycIAID-/- 
samples. For each category, the number of events in each repeat type and the 
fraction of all events falling in that type are shown. A Fisher‘s exact test was 
performed to compare AID sufficient and AID deficient frequencies. Total = 





Next, we examined whether IgHI and MycI capture DSB targets at similar rates. 
Indeed, in AID sufficient samples, total translocations from a given chromosome 





Figure 4.7. Translocations from MycI and IgHI to transchromosomal targets. 
Graph comparing the number of translocations per mappable megabase to each 
chromosome from IgHI (y axis) or MycI (x axis). 
 
 
This similarity could be explained by the close physical proximity of IgH and c-
myc, as suggested by studies with EBV-transformed B lymphoblastoid cells (Roix 
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et al., 2003). Alternatively, the correlation in trans-chromosomal joining might 
represent random ligation between I-SceI DSBs in IgH or c-myc and DSBs on 
other chromosomes. This might also be a function of gene density; chromosome 
7 and 11 are relatively gene rich while chromosome 3 is relatively gene poor. We 
conclude that extra-chromosomal DSBs ligate DSBs in IgHI and MycI at similar 
rates.  
 
To examine the nature of the intra-chromosomal rearrangement bias we 
calculated the ratio of IgHI to MycI captured events for each 500 kb segment of 
the genome and compared the values for chromosome 12 and 15 to the trans-
chromosomal joining average of 500kb windows genome-wide (Figure 4.8A). 
This analysis revealed that DSBs are preferentially captured intra-chromosomally 
and this effect diminishes at a rate inversely proportional to the distance from the 
I-SceI site (d-1.29) (Figure 4.8B). This effect was most prominent locally but was 
evident at up to ~50 Mb away from the I-SceI break. We conclude that paired 
DSBs are preferentially joined intra-chromosomally and that the magnitude of this 






Figure 4.8. Distance dependent intra-chromosomal rearrangements.  
(A) Ratio of IgHI captured to MycI captured events in 500 kb bins moving away 
from the I-SceI capture site (both directions combined). Dotted line represents 
the average trans-chromosomal joining frequency computed on all chromosomes 
other than 12 or 15. Gray areas show 2 standard deviations around the mean. 
(B) Modeling intra-chromosomal rearrangement bias. Rearrangements to IgHI 
(red) and MycI (blue) in the combined AIDRV samples were sorted into variable-
sized bins of ≥20 events. Rearrangement density was calculated per bin to the 
left and right of c-myc separately as a step plot.  When both directions were 
combined and plotted as a scatter plot on a log-log scale (inset graph, hotspots in 
grey) from 5 kb to 1 Mb, a roughly linear relationship suggested that the 
rearrangement density decreased as a function of a power of the distance. 
 Fitting a linear model to the log transformed data excluding hotspots allowed the 
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CHAPTER 5:  
Rearrangement Hotspots in Activated B 
Cells 
 
To determine whether there are hotspots for rearrangement, we searched the B 
cell genome for local accumulations of reads in AID deficient and sufficient 
samples. TC-Seq hotspots were defined as a localized enrichment of 
rearrangements above what is expected from a uniform genomic distribution. We 
removed likely artifacts; namely hotspots containing >80% of reads within DNA 
repeats, and those with footprints of <100nt (because translocations are 
amplified from randomly sonicated DNA (Figure 2.4A), deep-sequence tags 
associated with bona fide rearrangements are unlikely to map within a small 
region). We chose to omit these repeat alignments because while repeats may 
be analyzed in bulk (Table 4.2), the alignments from the reads may not be 
reliable. We identified 34 hotspots captured by MycI in the absence of AID (Table 
5.1). There were 31 hotspots in 17 genes and 3 in non-genic regions. 17 of the 
hotspots were in Pvt1, within 500 kb of the I-SceI site. 
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Repeat type and 
cryptic I-SceI 
chr15:61868606-
61882447 61 19296|Pvt1 in gene all 
chr15:61937605-
61948372 48 19296|Pvt1 in gene all 
chr15:61884209-
61895375 37 19296|Pvt1 in gene  
chr17:39980042-
39983459 36 751530|Mir715 in gene  
chr15:61905101-
61913127 27 19296|Pvt1 in gene all 
chr15:61896784-
61903467 26 19296|Pvt1 in gene 
line, sine, LTR, DNA, 
simple, DNA 
chr2:155630784-
155631968 26 17391|Mmp24 in gene  
chr7:112726654-
112731060 19 11785|Apbb1 in gene 
sine, line, near cryptic 
IsceI site 
chr15:61919292-
61924833 18 19296|Pvt1 in gene sine, ltr 
chr15:61928582-
61933207 17 19296|Pvt1 in gene 
line, sine, LTR, DNA, 
simple (GT, GA) 
chr15:81735124-
81735608 14 11429|Aco2 in gene  
chr15:61950188-
61954544 12 19296|Pvt1 in gene  
chr15:61914451-
61917481 11 19296|Pvt1 in gene  
chr1:137751600-
137752931 11 21956|Tnnt2 2762 near cryptic IsceI site 
chr15:61996073-
61999322 8 19296|Pvt1 in gene  
chr9:107230861-
107231335 7 69536|Hemk1 in gene sine 
chr15:16219195-




C02Rik in gene  
chr15:62050249-
62052811 7 19296|Pvt1 in gene  
chr14:46096170-
46097095 6 218952|Fermt2 in gene  
chr15:61989531-
61991172 6 19296|Pvt1 in gene  
chr2:155633401-
155634287 5 17391|Mmp24 in gene sine, line 
chrX:11376878-
11378216 5 71458|Bcor 235647 
LTR, near cryptic 
IsceI site 
chr15:62025428-
62027589 5 19296|Pvt1 in gene 




61987927 5 19296|Pvt1 in gene  
chr15:62075361-
62075946 4 19296|Pvt1 in gene line 
chr8:96450914-
96451204 4 14681|Gnao1 in gene simple (CA) 
chr7:6872248-
6872359 4 57775|Usp29 in gene simple (ca) 
chr19:44375405-
44375796 4 20250|Scd2 in gene near cryptic IsceI site 
chr2:132665496-
132665672 3 66634|Mcm8 in gene Sine, Simple (GT) 
chr15:61975151-




p5 21633  
chr15:62042419-




m174b in gene  
 
 
Table 5.1. TC-Seq hotspot list for MycIAIDKO B cells. For each hotspot the 
number of rearrangements constituting the hotspot, the closest gene, the 
distance to that gene, and the type of repetitive DNA elements contained in the 




In addition, 2 hotspots occurred within 5 kb of cryptic I-SceI sites (each bearing 
one mismatch to the 18- base pair recognition sequence). For example, one such 
hotspot at chr15:16219195-16219312 containing a 1-off I-SceI recognition 
sequence bore 8 rearrangements (Figure 5.1). A genome-wide search for 
rearrangements within 5 kb of cryptic I-SceI sites (83 within the mouse genome 
with 1 or 2 mismatches to the canonical I-SceI recognition sequence) yielded 57 
events, 7 times more than expected in a random distribution model. When 
allowing up to 6 mismatches we find a total of 5 out of 17 AID-independent 
hotspots near putative cryptic I-SceI sites. Although I-SceI has been used to 
generate a unique DSB in gene targeting and DNA repair experiments, our data 
suggest that DNA recognition by I-SceI can be promiscuous in the mouse 
genome, as demonstrated for other yeast endonucleases (Argast et al., 1998). 
 
Next, we searched the AID sufficient data sets for AID dependent hotspots. 
These were defined as genomic locations where there was at least a 10-fold 
enrichment over background rearrangement levels. In contrast to AID-/-, we found 
157 hotspots in 83 genes captured by IgHIAIDRV and 60 hotspots in 37 genes by 
MycIAIDRV in 100 million B cells. (Tables 5.2 and 5.3). This suggests that AID is 








Figure 5.1. I-SceI cryptic site screenshot. Screenshot showing a TC-Seq 
hotspot associated with a cryptic I-SceI site located on chromosome 15 in 
MycIAID-/- B cells. Rearrangements accumulate within 200 bp of a site that differs 















  chr12:114569045-114578835 2063 IgH|IgH in gene 
chr12:114600202-114603869 259 IgH|IgH in gene 
chr7:132695991-132699453 141 16190|Il4ra in gene 
chr13:43880182-43885076 132 12522|Cd83 in gene 
chr15:62001300-62004099 128 19296|Pvt1 in gene 
chr15:74761629-74764081 85 17069|Ly6e 21399 
chr11:61466811-61469564 74 71520|Grap in gene 
chr15:62009859-62012742 69 19296|Pvt1 in gene 
chr15:74785846-74789190 57 17069|Ly6e in gene 
chr17:29627912-29629491 49 18712|Pim1 in gene 
chr12:114665845-114667844 48 IgH|IgH in gene 
chr15:82040871-82042918 28 20788|Srebf2 5481 
chr10:53793003-53795422 27 17155|Man1a in gene 
chr7:52091757-52092909 25 14204|Il4i1 in gene 
chr15:34012782-34013570 24 67154|Mtdh in gene 
chr15:79724869-79726419 23 80287|Apobec3 in gene 
chr16:84706683-84708187 20 387173|Mir155 6197 
chr4:44714489-44715772 20 18507|Pax5 in gene 
chr16:84703741-84705601 19 387173|Mir155 8783 
chr8:129115681-129117132 17 270110|Irf2bp2 in gene 
chr15:62157722-62158587 15 19296|Pvt1 75192 
chr16:19061770-19063197 14 IgLlambda|IgLlambda in gene 
chr7:132747538-132748234 13 60504|Il21r in gene 
chr4:44716165-44717120 13 18507|Pax5 in gene 
chr11:87569331-87570257 12 387160|Mir142 108 
chr15:62000011-62000612 11 19296|Pvt1 in gene 
chr4:44722019-44722683 11 18507|Pax5 in gene 
chr6:70676375-70677272 11 IgLkappa|IgLkappa in gene 
chr9:44333604-44334132 9 12145|Cxcr5 in gene 
chr4:44981291-44982237 9 76238|Grhpr 12045 
chr11:86398867-86399824 9 75909|Tmem49 in gene 
chr15:74827015-74828130 8 110454|Ly6a in gene 
chr11:61470062-61470857 7 71520|Grap in gene 
chr8:35871344-35872045 7 319520|Dusp4 in gene 
chr6:129134035-129135134 7 93694|Clec2d in gene 
chr15:62160533-62161287 6 19296|Pvt1 78003 
chr15:61903483-61904141 6 19296|Pvt1 in gene 
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chr15:74784468-74785172 6 17069|Ly6e 308 
chr7:132750068-132750375 6 60504|Il21r in gene 
chr8:73223046-73223403 6 16478|Jund in gene 
chr9:107199973-107201059 6 12700|Cish in gene 
chr8:87501360-87502454 6 16477|Junb in gene 
chr15:82980236-82980359 5 104307|Rnu12 12 
chr12:114550576-114550791 5 IgH|IgH in gene 
chr3:95463197-95463519 5 17210|Mcl1 in gene 
chr10:17443755-17444131 5 17684|Cited2 in gene 
chr10:59681817-59682230 5 53374|Chst3 in gene 
chr10:59680759-59681209 5 53374|Chst3 in gene 
chr12:114551620-114552139 5 IgH|IgH in gene 
chr15:79913571-79914224 5 27367|Rpl3 in gene 
chr6:127100691-127101260 4 12444|Ccnd2 in gene 
chr15:61897189-61897630 4 19296|Pvt1 in gene 
chr15:74756575-74757098 4 17069|Ly6e 28382 
chr15:62156632-62157160 4 19296|Pvt1 74102 
chr13:46059069-46059856 4 20238|Atxn1 in gene 
chr12:114566773-114567144 4 IgH|IgH in gene 
chr15:62020486-62020920 4 19296|Pvt1 in gene 
chr9:44143288-44143844 4 15270|H2afx in gene 
chr17:35138064-35138737 4 22321|Vars in gene 
chr15:62105382-62105511 3 19296|Pvt1 22852 
 
Table 5.2. TC-Seq hotspots in MycIAIDRV B cells. For each hotspot the 
genomic location (chromosome:base#-base#), the number of events in that 
hotspot and its most proximal gene is shown. If a hotspot is in a gene the last 
column indicates this, if the hotspot is in an intergenic region the last column 
gives the number of bases away from the nearest gene. Only AID-dependent 
hotspots are shown. 
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Closest gene id|name Closest gene (nts) 
chr12:114563677-114583617 18010 IgH|IgH in gene 
chr12:114592880-114605961 3415 IgH|IgH in gene 
chr12:114464291-114473409 397 IgH|IgH 24991 
chr7:132695160-132701616 355 16190|Il4ra in gene 
chr12:113826127-113831888 306 70435|Inf2 in gene 
chr12:114477632-114487105 198 IgH|IgH 11295 
chr13:43880627-43885981 158 12522|Cd83 in gene 
chr12:114545002-114549279 149 IgH|IgH in gene 
chr16:84703733-84708651 142 387173|Mir155 5733 
chr11:61466722-61471367 129 71520|Grap in gene 
chr12:114550562-114553023 120 IgH|IgH in gene 
chr12:114487888-114495960 103 IgH|IgH 2440 
chr6:129131713-129135370 95 93694|Clec2d in gene 
chr6:70672635-70676968 90 IgLkappa|IgLkappa in gene 
chr12:81210545-81214030 89 12192|Zfp36l1 in gene 
chr17:29627857-29630975 74 18712|Pim1 in gene 
chr12:114529738-114534115 61 IgH|IgH in gene 
chr12:114460798-114463471 60 69195|Tmem121 33065 
chr7:132746979-132749248 58 60504|Il21r in gene 
chr16:58715676-58718789 52 71223|Gpr15 in gene 
chr7:52091646-52094659 49 100328588|Nup62-il4i1 in gene 
chr8:129115389-129117233 43 270110|Irf2bp2 in gene 
chr15:61817197-61819111 42 17869|Myc in gene 
chr12:116745900-116747837 38 IgH|IgH in gene 
chr10:53793549-53795607 38 17155|Man1a in gene 
chr12:115526476-115529230 35 IgH|IgH in gene 
chr11:87569636-87571044 31 387160|Mir142 in gene 
chr12:115984499-115986323 29 IgH|IgH in gene 
chr12:114560586-114562879 29 IgH|IgH in gene 
chr12:116861441-116863848 27 IgH|IgH in gene 
chr12:117150666-117151414 27 IgH|IgH in gene 
chr12:88539032-88541058 27 382620|Tmed8 in gene 
chr12:115821793-115822684 26 IgH|IgH in gene 
chr12:114096947-114100451 26 56696|Gpr132 in gene 
chr16:19061101-19062590 26 IgLlambda|IgLlambda in gene 
chr12:116152849-116154287 25 IgH|IgH in gene 
chr13:63896445-63900869 25 76251|0610007P08Rik 15758 
chr3:135352008-135353935 24 18033|Nfkb1 in gene 
chr9:107199367-107200994 20 12700|Cish in gene 
chr17:51970428-51972180 20 20230|Satb1 in gene 
chr12:114606862-114609279 20 IgH|IgH in gene 
chr12:114557649-114560033 19 IgH|IgH in gene 
chr3:95462675-95465208 19 17210|Mcl1 in gene 
chr11:106173700-106175830 19 15985|Cd79b in gene 
chr12:114835673-114836176 18 IgH|IgH in gene 
chr11:115487516-115488927 18 67283|Slc25a19 in gene 
chr12:116886227-116888201 17 IgH|IgH in gene 
chr12:115097413-115098823 17 IgH|IgH in gene 
 107 
chr11:86398657-86400144 17 75909|Tmem49 in gene 
chr16:19065068-19066725 17 IgLlambda|IgLlambda in gene 
chr8:35870456-35872041 15 319520|Dusp4 in gene 
chr12:70298030-70299253 15 109065|1110034A24Rik in gene 
chr8:73223130-73224638 15 16478|Jund in gene 
chr12:117158582-117159779 14 IgH|IgH in gene 
chr12:115630002-115631365 14 IgH|IgH in gene 
chr9:107201768-107203198 13 12700|Cish in gene 
chr14:122361101-122363562 13 321019|Gpr183 in gene 
chr12:116532327-116532749 12 IgH|IgH in gene 
chr12:116383843-116384804 12 IgH|IgH in gene 
chr12:56591584-56593525 12 18035|Nfkbia in gene 
chr12:117086102-117086768 11 IgH|IgH in gene 
chr12:70397988-70398524 11 69554|Klhdc2 in gene 
chr4:44725889-44726961 11 18507|Pax5 2577 
chr7:133556483-133558100 10 12478|Cd19 in gene 
chr13:53014444-53014988 10 11992|Auh in gene 
chr12:115560605-115561181 10 IgH|IgH in gene 
chr4:44980880-44981502 10 76238|Grhpr 12780 
chr13:23713187-23714124 10 50709|Hist1h1e in gene 
chr3:96073011-96074020 10 319189|Hist2h2bb in gene 
chr12:87027653-87028719 10 53314|Batf in gene 
chr4:44715829-44717064 10 18507|Pax5 in gene 
chr2:158492484-158494071 10 228852|Ppp1r16b in gene 
chr13:53072809-53074649 10 18030|Nfil3 in gene 
chr9:44333703-44334267 10 12145|Cxcr5 in gene 
chr12:115076892-115077564 9 IgH|IgH in gene 
chr12:115391414-115392751 9 IgH|IgH in gene 
chr2:166888980-166890860 9 68949|1500012F01Rik in gene 
chr12:115776774-115777349 9 IgH|IgH in gene 
chr8:87501548-87502456 9 16477|Junb in gene 
chr12:114610038-114611149 8 IgH|IgH in gene 
chr9:44412166-44412743 8 13209|Ddx6 231 
chr16:58672312-58673522 8 12892|Cpox in gene 
chr1:108068896-108070111 8 98432|Phlpp1 in gene 
chr12:115232761-115233011 8 IgH|IgH in gene 
chr12:115707425-115707742 8 IgH|IgH in gene 
chr12:114955011-114955614 8 IgH|IgH in gene 
chr6:136752518-136753244 8 320332|Hist4h4 in gene 
chr12:114555430-114556333 8 IgH|IgH in gene 
chr10:59681922-59682995 8 53374|Chst3 in gene 
chr12:116175390-116175840 7 IgH|IgH in gene 
chr12:115008112-115009040 7 IgH|IgH in gene 
chr8:97269761-97270072 7 20299|Ccl22 in gene 
chr12:116733901-116734666 7 IgH|IgH in gene 
chr12:117072263-117072562 7 IgH|IgH in gene 
chr6:129130592-129131098 7 93694|Clec2d in gene 
chr12:115717148-115717715 7 IgH|IgH in gene 
chr12:116229318-116230137 7 IgH|IgH in gene 
chr4:44714015-44714884 7 18507|Pax5 in gene 
chr12:114553758-114554896 7 IgH|IgH in gene 
chr15:74785673-74786897 7 17069|Ly6e in gene 
chr16:10784789-10785123 7 12703|Socs1 in gene 
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chr15:74763628-74764024 7 17069|Ly6e 21456 
chr12:115134720-115134990 6 IgH|IgH in gene 
chr7:132750171-132750297 6 60504|Il21r in gene 
chr17:35136839-35137019 6 22321|Vars 832 
chr12:116831379-116831823 6 IgH|IgH in gene 
chr4:44721635-44722251 6 18507|Pax5 in gene 
chr12:115414770-115415436 6 IgH|IgH in gene 
chr15:79911701-79912444 6 27367|Rpl3 in gene 
chr13:51942199-51943030 6 23882|Gadd45g in gene 
chr6:48655721-48656684 6 231931|Gimap6 in gene 
chr15:82041126-82042151 6 20788|Srebf2 5736 
chr1:36365470-36366278 5 214855|Arid5a in gene 
chr12:116396756-116396922 5 IgH|IgH in gene 
chr11:5421596-5421866 5 22433|Xbp1 in gene 
chr12:116930165-116930446 5 IgH|IgH in gene 
chr12:115251470-115251824 5 IgH|IgH in gene 
chr3:96024349-96024764 5 319176|Hist2h2ac in gene 
chr15:74787652-74788420 5 17069|Ly6e in gene 
chr12:114729327-114730211 5 IgH|IgH in gene 
chr12:114497586-114498517 5 IgH|IgH in gene 
chr6:48696841-48697785 5 317757|Gimap5 in gene 
chr11:61472162-61473172 5 71520|Grap in gene 
chr12:55797689-55797969 5 66266|Eapp 837 
chr12:117107309-117107806 5 IgH|IgH in gene 
chr12:92827477-92828227 5 83602|Gtf2a1 in gene 
chr2:34812256-34812641 4 22029|Traf1 in gene 
chr12:115609552-115610249 4 IgH|IgH in gene 
chr12:115855867-115856592 4 IgH|IgH in gene 
chr6:48634895-48635772 4 107526|Gimap4 in gene 
chr12:115117746-115118111 4 IgH|IgH in gene 
chr9:32347803-32348302 4 14247|Fli1 in gene 
chr2:127952144-127952647 4 12125|Bcl2l11 in gene 
chr12:115298061-115298583 4 IgH|IgH in gene 
chr12:113858703-113859237 4 11565|Adssl1 in gene 
chr17:88463676-88464261 4 225055|Fbxo11 in gene 
chr1:162966442-162967042 4 14455|Gas5 in gene 
chr13:21871724-21872334 4 56702|Hist1h1b in gene 
chr15:34012549-34013176 4 67154|Mtdh in gene 
chr6:48689187-48689841 4 16205|Gimap1 in gene 
chr7:108257838-108258501 4 207278|Fchsd2 in gene 
chr16:10783339-10784041 4 12703|Socs1 in gene 
chr10:59413651-59414365 4 74747|Ddit4 in gene 
chr14:70688210-70689003 4 19057|Ppp3cc in gene 
chr12:115252782-115253686 4 IgH|IgH in gene 
chr4:134479505-134480566 4 27981|D4Wsu53e in gene 
chr12:115187722-115188045 4 IgH|IgH in gene 
chr13:63895201-63895639 4 76251|0610007P08Rik 20988 
chr16:58720437-58720884 4 71223|Gpr15 1600 
chr7:132634208-132634668 4 67711|Nsmce1 in gene 
chr12:116011816-116012535 4 IgH|IgH in gene 
chr10:59634442-59634618 3 53374|Chst3 9657 
chr12:117238411-117238513 3 IgH|IgH in gene 
chr1:38720806-38720934 3 16764|Aff3 in gene 
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chr4:44724505-44724640 3 18507|Pax5 1193 
chr12:116550486-116550640 3 IgH|IgH in gene 
chr5:114281912-114282032 3 20345|Selplg 1402 
 
 
Table 5.3. TC-Seq hotspots in IgHIAIDRV B cells. For each hotspot the 
genomic location (chromosome:base#-base#), the number of events in that 
hotspot and its most proximal gene is shown. If a hotspot is in a gene the last 
column indicates this, if the hotspot is in an intergenic region the last column 
gives the number of bases away from the nearest gene. Only AID-dependent 
hotspots are shown. 
 
 
Next, we sought to characterize the nature of AID targets. Consistent with a 
translocation coupled targeting mechanism, 80% of the AID-dependent hotspots 
captured by c-myc and 90% of those captured by IgH were within genes. For 
example, we found robust AID-dependent hotspots on Il4i1 and Pax5 (a recurring 
IgH translocation partner in lymphoplasmacytoid lymphoma (Kuppers, 2005)) 












Figure 5.2. Screenshots of AID-dependent rearrangement hotspots. 
Translocations per 100 bp present at Il4i1 and Pax5 genes in all samples. Arrows 




 AID-dependent hotspots were similar for IgHI B cells expressing wild type levels 
(WT) or retrovirally over-expressed (RV) AID, however the number of TC-Seq 
captured events per hotspot was decreased in the former (Figures 5.2 and 5.3). 
Therefore, translocations to AID targets occur in cells expressing physiological 
levels of AID and hotspots are not dependent on AID over-expression. 3 hotspots 
observed in AIDWT samples but not AIDRV samples are likely due to experimental 
variability. We conclude that AID produces substrates for translocations in a 






Figure 5.3. Overlap of hotspots in AIDWT and AIDRV IgHI samples. Venn 
diagram showing the number of shared and exclusive AID-dependent hotspot-
bearing genes in IgHIAIDRV and IgHIAIDWT experiments. 
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Consistant with equal capture rates of extrachromosomal targets by c-myc and 
IgH (Figure 4.7) Genes containing AID-dependent hotspots overlapped between 





Figure 5.4. Overlap of hotspots in IgHIAIDRV, MycIAIDRV and MycIAIDKO 
samples. Venn diagram showing the number of shared and exclusive AID-
dependent hotspot-bearing genes in the three experiments. 
 
 
We found that 28 of the frequently translocated targets were shared. In contrast, 
there were a number of unique intra-chromosomal AID-dependent hotspots. For 
example, rearrangements to Inf2 on chromosome 12 (~850 kb from IgHI) were 
only found by IgHI capture while rearrangements near Pvt1 on chromosome 15 
(up to ~350 kb from MycI) were only found by MycI capture (Tables 5.2 and 5.3). 
Thus, there is a bias towards recombination between I-SceI breaks and AID 
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hotspots within the same chromosome. Additionally, the finding that some 
hotspots are only captured in cis indicates that TC-Seq underestimates the 
number of AID mediated DSBs in the genome and suggests that we have not 
reached saturation. Additionally, we note that AID-independent hotspots do not 
arise in the AID-sufficient sample. We propose that this is due to a higher 
availability of AID-generated DSBs, which saturate the rearrangement profile to I-
SceI generated ends. 
 
Combined analysis of the IgHI and MycI TC-Seq data sets and mRNA-Seq data 
shows that AID dependent hotspots are primarily found in transcribed genes 
(Figure 5.5A). However, while nearly all of the translocated genes are actively 
transcribed, there is no clear correlation between transcript abundance and 
rearrangement frequency (Figure 5.5B). Furthermore, ~2000 highly transcribed 
genes are not rearranged (Figure 5.5A, shaded area). Therefore transcription is 
necessary but not sufficient for AID targeting, and transcription levels alone 
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Figure 5.5. Correlating AID dependent hotspots with transcription.  
(A) Empirical cumulative distribution analysis showing transcript abundance in 
genes displaying (red) or lacking (black) AID dependent rearrangement hotspots. 
Filled-in gray slice represents ~2000 highly transcribed yet unrearranged genes. 
(B) Total rearrangements as a function of gene expression (mRNA-Seq) 
(Yamane et al., 2011) in genes bearing AID dependent rearrangement hotspots. 




Additionally, AID-dependent hotspots are biased to the region around the 
transcription start site (Figure 5.6A). This finding is consistent with the 
accumulation of AID and Spt5 around the promoters of stalled genes and the 
distribution of somatic hypermutation (Pavri et al., 2010; Yamane et al., 2011). 
Indeed, AID-dependent TC-Seq hotspots overlap with regions of AID and Spt5 
accumulation (Figures 5.6B and 5.7). 
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Figure 5.6. Genomic features at AID-dependent hotspots. (A) Composite 
density graph showing the distribution of rearrangements in genes associated 
with AID dependent hotspots relative to the TSS. (B) Spt5 and AID recruitment at 
genomic sites associated with translocation hotspots (Pavri et al., 2010; Yamane 




Figure 5.7. AID loading at AID-dependent rearrangement hotspots. 
Empirical cumulative distribution function showing AID accumulation at TSSs of 
genes displaying (red) or lacking (black) AID-dependent TC-Seq hotspots. AID 




This correlation prompted us to explore the relationship between AID activity and 
accumulation of chromosomal translocations by measuring somatic 
hypermutation at TC-Seq captured AID targets (Yamane et al., 2011) (Table 5.4). 
To increase sensitivity we examined AID mediated mutations in IgKAID/UNG-/- B 
cells (AID over expression by virtue of a VKappa promoter increases AID levels 
and therefore, mutation rates). In the absence of UNG mutation rates are further 
increased because U:G mismatches are processed into mutations rather than 
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DSBs (Schrader et al., 2005; Xue et al., 2006). We found a positive correlation 
(Spearman coefficient = 0.84) between hypermutation and rearrangement 
frequency (Figure 5.8). All genes analyzed with a mutation frequency over 10x10-
5 bear rearrangements, and all genes with AID-dependent TC-Seq hotspots show 
mutations (Figure 5.8). Rearrangements were only seen rarely in genes with 
lower rates of mutation. This suggests that the frequency of hypermutation and 
the frequency of AID-induced DSBs are directly proportional. We conclude that 
AID-dependent TC-Seq hotspots occur on stalled genes that can accumulate 
Spt5, AID, and may suffer hypermutation relative to background levels.  
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IgSm IgkAID-Ung-/- 26101 521 1996  1.00E-08 Aicda-/- 26369 0  <1  
IgSg1 IgkAID-Ung-/- 18255 286 1567  1.00E-08 Aicda-/- 28270 0  <1  
Pim1 IgkAID-Ung-/- 20453 41 200.5  1.00E-08 Aicda-/- 17219 1  5.8  
Mir142 IgkAID-Ung-/- 21551 43 199.5  1.00E-08 Aicda-/- 23676 1  4.22  
Myc IgkAID-Ung-/- 103818 171 164.7  2.17E-06 Aicda-/- 19136 3  15.7  
Jh4 
intron 
IgkAID-Ung-/- 17223 26 151.0  1.00E-08 
Aicda-/- 14640 2  13.7  
Il4ra IgkAID-Ung-/- 29062 35 120  5.36E-08 Aicda-/- 25257 2  7.92  
Nfkb1 IgkAID-Ung-/- 22734 26 114.37  1.28E-05 Aicda-/- 12838 0  0  
Mir21 IgkAID-Ung-/- 25583 27 105.53  2.60E-08 Aicda-/- 23454 0  0  
Grap IgkAID-Ung-/- 19084 19 99.6  1.55E-04 Aicda-/- 12402 0  <1  
Mir155 IgkAID-Ung-/- 27677 26 93.94  1.00E-08 Aicda-/- 31614 0  0  
Csk IgkAID-Ung-/- 37807 31 82.00  3.92E-05 Aicda-/- 33267 5  15.03  
Pax5 IgkAID-Ung-/- 114476 81 70.70  9.00E-04 Aicda-/- 28035 4  14.27  
Hist1h1c IgkAID-Ung-/- 42680 34 79.7  2.52E-06 Aicda-/- 34266 3  8.8  
Ly6e IgkAID-Ung-/- 20583 13 63.2  2.61E-03 Aicda-/- 13546 0  <1  
Cd83 IgkAID-Ung-/- 11577 7 60.5  3.59E-05 Aicda-/- 38378 0  <1  
H2afx IgkAID-Ung-/- 23611 12 55.1  1.81E-03 Aicda-/- 18630 0  <1  
Gadd45g IgkAID-Ung-/- 23728 13 54.8  5.25E-04 Aicda-/- 27482 1  3.6  
Apobec3 IgkAID-Ung-/- 37505 18 47.99  3.10E-03 Aicda-/- 16440 0  0  
Clec2d IgkAID-Ung-/- 50996 22 43.14  1.20E-07 
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Aicda-/- 67695 1  1.47  
Ikzf1 IgkAID-Ung-/- 34994 15 42.86  1.05E-02 Aicda-/- 36302 4  11.02  
Il4i1 IgkAID-Ung-/- 41757 14 38.3  1.14E-03 Aicda-/- 55503 3  5.4  
Adrbk1 IgkAID-Ung-/- 23333 8 34.3  2.45E-02 Aicda-/- 17277 0  <1  
Hvcn1 IgkAID-Ung-/- 24912 8 32.1  2.45E-01 Aicda-/- 21033 3  14.3  
Bcl11a IgkAID-Ung-/- 38265 12 31.36  1.50E-02 Aicda-/- 34092 2  5.87  
Actb IgkAID-Ung-/- 25984 7 26.9  1.62E-02 Aicda-/- 23858 0  <1  
Ucp2 IgkAID-Ung-/- 22139 5 22.6  1.69E-02 Aicda-/- 27937 0  <1  
Gpr15 IgkAID-Ung-/- 37789 7 18.52  3.15E-01 Aicda-/- 29540 2  6.77  
Pip5k1c IgkAID-Ung-/- 36102 6 16.6  3.16E-02 Aicda-/- 56600 1  1.8  
Dpagt1 IgkAID-Ung-/- 26430 4 15.1  5.48E-02 Aicda-/- 48791 1  2.1  
Lman1 IgkAID-Ung-/- 29569 3 10.14  3.31E-01 Aicda-/- 36662 1  2.72  
Sfrs9 IgkAID-Ung-/- 32871 3 9.12  6.69E-01 Aicda-/- 37790 2  5.29  
Trex1 IgkAID-Ung-/- 34574 3 8.68  2.59E-01 Aicda-/- 27625 0  <1  
Blr1 IgkAID-Ung-/- 36549 3 8.21  5.73E-01 Aicda-/- 38924 1  2.57  
IgCm IgkAID-Ung-/- 45906 4 8.71  3.29E-01 Aicda-/- 25726 0  <1  
Cdc42 IgkAID-Ung-/- 28015 2 7.14  5.05E-01 Aicda-/- 22838 0  <1  
Hmbs IgkAID-Ung-/- 28566 2 7.00  2.08E-01 Aicda-/- 34058 0  <1  
Eif3h IgkAID-Ung-/- 33048 2 6.05  5.01E-01 Aicda-/- 30948 0  <1  
Rpl4 IgkAID-Ung-/- 34352 2 5.82  5.02E-01 Aicda-/- 30600 0  <1  
Rbbp7 IgkAID-Ung-/- 22472 1 4.44  4.58E-01 Aicda-/- 26602 0  <1  
Crk IgkAID-Ung-/- 27511 1 3.63  1.00E+00 Aicda-/- 28215 1  3.54  
Spib IgkAID-Ung-/- 28941 1 3.45  1.00E+00 Aicda-/- 27684 0  0  
Fam50a IgkAID-Ung-/- 34086 1 2.93  6.14E-01 Aicda-/- 32154 2  6.22  
Aicda IgkAID-Ung-/- 35479 1 2.82  1.00E+00 Aicda-/- 25717 0  0  
Gdi2 IgkAID-Ung-/- 31044 0 <1  2.48E-01 Aicda-/- 30772 2  6.5  
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N-myc IgkAID-Ung-/- 45462 0 <1  1.00E+00 Aicda-/- 31251 0  <1  
Repeat 
1* 
IgkAID-Ung-/- 34173 3 8.73  _ 
Aicda-/- na _  _ _ 
Repeat 
2** 
IgkAID-Ung-/- 39636 0 0.00  _ 
Aicda-/- na _  _  
Repeat 
3*** 
IgkAID-Ung-/- 48809 1 2.05  _ 
Aicda-/- na _  _  
Serinc3 IgkAID-Ung-/- 48237 2 4.15  _ Aicda-/- na _  _  
Mir715 IgkAID-Ung-/- 46081 11 23.87  5.51E-01 Aicda-/- 44285 14  31.61  
*chr19:28,942,810-28,943,877     
**chr11:27,022,268-27,023,001     




Table 5.4. Hypermutation analysis. Genes were analyzed using DNA isolated 
from IgkAID/Ung-/- or Aicda-/- LPS + IL-4activated B cells (Robbiani et al., 2009). 
Genes marked in yellow were analyzed de novo and added to a previous 
hypermutation survey (Yamane et al., 2011). bp: total number of bp sequenced. 
Mutations: total number of mutations detected. p value was calculated between 






Figure 5.8. Translocation frequency versus mutation frequency in AID 
targeted genes. Each gene was plotted as a function of its mutation rate in 
IgKAID/Ung-/- B cells and its rearrangement frequency as determined by TC-Seq. 
 
 
Among AID-dependent hotspot containing genes we find several that are 
translocated or deleted in mature B cell lymphoma. These include Pax5/IgH, 
Pim1/Bcl6, Il21r/Bcl6, Gas5/Bcl6 and Ddx6/IgH translocations and Junb and 
Socs1 deletions in diffuse large B cell lymphoma, Birc3/Malt1 translocation in 
MALT lymphoma, Ccnd2/IgK translocation and Bcl2l11 deletion in mantle cell 
lymphoma, Aff3/Bcl2 and Grhpr/Bcl6 translocations in follicular lymphoma, 
mir142/c-myc translocation in B cell prolymphocytic leukemia as well as c-




Table 5.5. AID-dependent rearrangements in human B cell lymphoma. 
TC-Seq Gene Translocation in Mature BCL Mature BCL Type Reference 
Birc3 (Api2) t(11;18)(q21;q21) MALT (Rosebeck et al., 2011) 
Il21r t(3;16)(q27;p11) DLBCL (Ueda et al., 2002) 
Pax5 t(9;14)(p13;q32) DBLCL (Iida et al., 1999) 
Pim1 t(3;6)(q27;p21.2) DLBCL (Yoshida et al., 1999) 
Aff3 t(2;18)(q11.2;q21) FL (Impera et al., 2008) 
Gas5 t(1;3)(q25;q27)  DLBCL (Nakamura et al., 2008) 
Ccnd2 t(2;12)(p12;p13) MCL (Gesk et al., 2006) 
c-myc t(8;14)(q23;q32) BL (Kuppers, 2005) 
Ddx6 (Rck) t(11;14)(q23;q32) DLBCL (Lu and Yunis, 1992) 
Grhpr t(3;9)(q27;p11) FL (Akasaka et al., 2003) 
Bcl2l11 Deleted MCL (Bea et al., 2009) 
Socs1 Deleted DLBCL (Mottok et al., 2009) 
Junb Deleted DLBCL (Mao et al., 2002) 
mir142 t(8;17) B-PLL (Gauwerky et al., 1989) 
Pvt1 t(2;8)(p11.2;q24.1) BL (Einerson et al., 2006) 
IgH several several (Kuppers, 2005) 
IgK several several (Kuppers, 2005) 
IgL several several (Kuppers, 2005) 
 
Table 5.5. AID-dependent rearrangements in human B cell lymphoma. 
Genes bearing AID-dependent TC-Seq hotspots are shown with the associated 
translocation or deletion observed in human mature B cell lymphoma (BCL). BCL 
types are abbreviated as follows: MALT (mucosa-associated lymphoid tissue 
lymphoma), DLBCL (diffuse large B cell lymphoma), FL (follicular lymphoma), 
MCL (mantle cell lymphoma), BL (Burkitt’s lymphoma), B-PLL (B cell 
prolymphocytic leukemia).  
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Interestingly, we find that AID is capable of inducing DSBs in Fli1 (Table 5.3), 
which is translocated to EWS in 90% of Ewing’s sarcomas, a malignant tumor of 
uncertain origin (Riggi and Stamenkovic, 2007). We conclude that in addition to 
mutating many genes, AID also initiates DSBs in numerous non-Ig genes. These 
genes serve as substrates for translocations associated with mature B-cell 






CHAPTER 6:  
Discussion 
 
To date, the study of chromosomal aberrations has been primarily limited to 
events identified in tumors and tumor cell lines. Although we have learned a great 
deal about the importance of genomic rearrangements in cancer, it has not been 
possible to develop an understanding of the cellular and molecular forces that 
govern their genesis. To examine genomic rearrangements in primary cells in 
short term cultures, we developed a technique to catalog these events by deep 
sequencing, TC-Seq. Using this technique we have obtained the complete 
recombinomes of two genes, c-myc and IgH, in activated B cells in the presence 
and absence of AID. Our analysis of over 180,000 rearrangements reveal the 
importance of transcription, chromosome territories and physical proximity in 
recombinogenesis, and identifies hotspots for AID-mediated translocations in 
mature B cells. Our data also suggest that non-Ig DSBs induced by AID are an 
important source of genomic instability in the mature B cell lymphomas. Finally, 
TC-Seq is a widely applicable technique; it can be adapted to study translocation 
biology is any tissue or cell type and to discover the location and nature of other 





Nuclear Proximity and Chromosomal Position 
  
The existence of chromosome territories, regions in which individual 
chromosomes segregate, has been long proposed (Cremer and Cremer, 2001) 
and recently shown to be a key feature of genome organization and determinant 
locus proximity (Lieberman-Aiden et al., 2009). However, until now the degree to 
which this impacts the genomic rearrangement landscape was unclear. Our 
analysis provides evidence that physical proximity and chromosome territories 
are partial determinants for joining of rearrangement partners. First, we find that 
rearrangements tend to occur intra-chromosomally. For example, when a DSB is 
introduced in c-myc 40% of rearrangements to that site occur on chromosome 
15. This observation is consistent with the analysis of rearrangements in breast 
cancer genomes, which showed that 92% of events occur intra-chromosomally 
and involve joining of DSBs within 2 Mb of each other (Stephens et al., 2009). 
Furthermore, since our experiments were performed in primary cells we can 
conclude that this phenomenon is a basic feature of rearrangement, not a result 
of cancer cell specific effects or selection.  
 
We find that the effects of physical proximity are most evident in the 350 kb 
region around a DSB. In both the absence and presence of AID, the plurality of 
rearrangements fall in this region. Interestingly, this marked preference for DSB 
repair within 350 kb matches the range of γH2AX spreading from a DSB 
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(Bothmer et al., 2010; Savic et al., 2009). γH2AX is a marker of the DNA damage 
response, which has been shown to spread widely around the site of a DSB, 
perhaps marking the extent of the DNA damage focus. It has been hypothesized 
that that the DNA damage response facilitates proximal rearrangement, a 
phenomenon most prominent at the IgH locus during CSR. (Bothmer et al., 
2011). Our observed preference for local repair might reflect this fact. 
 
The magnitude of the effect of chromosome territories on rearrangement is far 
less prominent than proximal joining, but is consistent with recent genome 
mapping data obtained by high-throughput chromosome conformation capture 
(Hi-C) (Lieberman-Aiden et al., 2009). When compared to trans-chromosomal 
joining, we find that a bias to intra-chromosomal rearrangements is evident even 
when as much as 50 Mb separates DSBs. In mouse, the mean autosome size is 
~130 Mb, so a 50 Mb preference for intra-chromosomal joining on either side of a 
DSB will encompass nearly the entire average chromosome. An intra-
chromosomal joining bias is evident in the preferential joining of AID hotspots and 
non-hotspots on chromosome 12 and chromosome 15 with their respective I-SceI 
breaks. When a break occurs in IgH the AID target inf2 ~1 Mb from the break 
appears as a robust hotspot, but when a break occurs in c-myc, inf2 is not 
captured. The inverse occurs for pvt1 exon 5, an AID target on chromosome 15 
that is captured by c-myc but not by IgH. We conclude that intra-chromosomal 
joining is preferred to trans-chromosomal joining.  
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Hi-C data shows that intra-chromosomal contact probability is inversely 
proportional to distance and obeys a power law scaling with a slope of –1.08 
(Lieberman-Aiden et al., 2009). We find that this closely matches the behavior of 
a DSB. Rearrangement density decreases as a power function of the distance 
from a break. The exponent of this power law is -1.29, close to the Hi-C estimate 
of -1.08. Since rearrangement density diminishes with distance in a manner 
similar to contact probability, it is mediated by proximity, a likely consequence of 
local chromosome packing and nuclear chromosomal territories. We conclude 
that the nuclear organization of chromosome territories impacts the 
rearrangement landscape and is a determinant of rearrangement propensity. 
Functionally, a strong preference for proximal intra-chromosomal rearrangement 
minimizes gross genomic alterations. We propose that this may be an important 





Transcription is associated with increased rates of DNA damage and genome 
instability; these effects are likely mediated by a number of different mechanisms 
(Gottipati and Helleday, 2009). Transcription may expose ssDNA, which is 
susceptible to chemical or oxidative damage (Aguilera, 2002). Additionally, head-
on collision of the replication and transcription machinery has been implicated in 
fork stalling and genomic instability (Takeuchi et al., 2003). While these 
phenomena have been well documented, it remains unclear which is the primary 
contributor to transcription associated instability and if this is a major mechanism 
of instability genome-wide. 
 
TC-Seq data suggests that transcription associated instability plays a key role in 
genome instability. First, in the case of the c-myc locus, transcription increases 
the size of the local area around a DSB that is available for recombination from 
50 kb to 300 kb. Rearrangements appear throughout the transcribed pvt1 gene; 
this suggests that transcription is indeed recombinogenic. Perhaps more striking, 
I-SceI breaks rearrange predominantly to transcribed genes genome-wide. We 
find that in the absence of AID, ~50% of rearrangements occur to genes; 
whereas only 40% of the genome is genic, this represents a significant 
enrichment. Rearrangements also tend to occur in transcribed genes, and appear 
to increase proportionally with transcription levels; significantly more 
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rearrangements than expected occur to highly transcribed genes while 
significantly less than expected occur to silent genes. This data is further 
supported by the finding that activating histone mark association and PolII 
loading tends to occur on rearranged genes, but not on genes lacking 
rearrangements. A bias for rearrangement between genic regions was also 
reported in recent studies on tumors; in sequenced breast cancer genomes 50% 
of rearrangements occur to genes (Stephens et al., 2009). However, in these 
studies the role of transcription, transformation or selection in these events could 
not be evaluated. Our experiments demonstrate that transcribed genic regions 
are over-represented in chromosomal rearrangements in primary cells in short-
term cultures. Thus, this likely represents a general principle underlying 
recombinogenesis genome-wide.  
 
There are several non-mutually exclusive explanations for our results. They may 
be a consequence of increased instability at transcribed genes, increased 
recombinogenicity of transcribed genes or simple physical proximity. Composite 
density analysis of the genic rearrangement profile implicates ssDNA instability 
as a major contributor to transcription associated recombination. The plurality of 
genic rearrangements occur to the transcription start site (TSS). The TSS is a site 
of substantial KMnO4 sensitivity along the gene body, and thus the primary site of 
ssDNA through the gene (Nechaev et al., 2010; Zhang and Gralla, 1989). And, 
as discussed in the introduction, ssDNA has documented sensitivity to damage 
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as compared to dsDNA (Frederico et al., 1990; Zhang and Gralla, 1989). Thus, 
we suggest that exposed ssDNA serves as a major source of genomic instability 
that predisposes transcribed genes to damage and rearrangement. 
 
In addition to being more susceptible to damage, this effect may be due to 
proximity. c-myc is transcribed in activated B cells, and, Hi-C experiments show 
that transcribed regions are spatially associated in the nucleus (Lieberman-Aiden 
et al., 2009). Therefore, the proximity of c-myc to other transcribed genes might 
contribute to a bias for genic rearrangements. Additionally, we find that c-myc 
and IgH translocate to both AID-dependent and -independent extra-chromosomal 
targets at similar rates. FISH experiments in cytogenetically normal lymphoma 
cell lines demonstrate that IgH and c-myc are in relatively close proximity (Roix et 
al., 2003). Thus, similar rearrangement profiles of c-myc and IgH might be the 
result of a shared nuclear neighborhood, the inhabitants of which are determined 
by transcriptional activity.  
 
Whatever the origin, we speculate that this phenomenon may have 
consequences for tumorigenesis. The rearrangement of proto-oncogenes to 
transcribed regions may lead to their dysregulation by placing them next to 
constitutively active promoters. Alternatively, rearrangements of coding regions to 
one another might produce fusion proteins that alter cellular metabolism, as is the 
case in CML.  
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AID and Chromosome Translocation 
 
AID initiates SHM and CSR by deaminating cytosine residues in ssDNA exposed 
by transcription (Chaudhuri and Alt, 2004; Di Noia and Neuberger, 2007; 
Nussenzweig and Nussenzweig, 2010; Peled et al., 2008; Stavnezer et al., 
2008). A primary site of AID activity is the IgH locus, where it generates DSBs 
(Petersen et al., 2001). In addition to participating in the physiological 
recombination reactions, these breaks may also partner in the generation of 
chromosomal rearrangements. Indeed, in many of the mature B cell lymphomas 
IgH is translocated to proto-oncogenes thereby dysregulating their expression 
and driving tumorigenesis (Kuppers, 2005). Until recently, the source of breaks in 
non-Ig genes translocated in mature B cell lymphomas was largely unknown. In 
2008, Robbiani and colleagues demonstrated that AID generates DSBs in c-myc, 
which is translocated in Burkitt’s lymphoma (Robbiani et al., 2008). They showed 
one year later that AID deregulation can affect tumor growth in a mouse model of 
B cell lymphomagenesis, in some cases targeting mir-142 for translocation 
(Robbiani et al., 2009). Thus, the retinue of non-Ig genes conclusively shown to 
suffer AID mediated DSB was 2, c-myc and mir-142. 
 
Other studies have suggested additional DSB targets of AID. Liu and colleagues 
sequenced 118 genes from germinal center B cells and showed that AID was 
capable of mutating 25% of them (Liu et al., 2008). This study suggested that AID 
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may act promiscuously, but it examined a very limited number of loci and only 
analyzed mutations, not DSBs. Subsequent genome-wide studies examined the 
locus association of certain factors by ChIP-Seq, elucidating AID’s targeting 
mechanism and extending the catalog of potential AID targets. Pavri and 
colleagues showed that the IgH locus and the TSSs of stalled genes load Spt5, a 
PolII stalling factor (Pavri et al., 2010). AID interacts with Spt5, which associates 
with thousands of loci, specifically at the TSS of stalled genes. AID ChIP-Seq 
confirmed the presence of AID on genes that load Spt5 (Yamane et al., 2011). 
Both the Spt5 and AID ChIP-Seq studies included mutational analysis of a few 
loci in a fixed position of the gene body, but lacked a direct measurement of AID 
activity genome-wide (Pavri et al., 2010; Yamane et al., 2011). Without such a 
measure, these studies remain suggestive. Moreover, to date no method exists 
to perform an unbiased examination of AID-mediated DSBs or translocations. 
Therefore, the precise relationships between AID and Spt5 occupancy, mutation, 
and translocations have not been investigated. 
 
Here, we provide the first genome-wide direct measurement of AID activity and 
the first unbiased analysis of AID-mediated DSBs. First, we show that AID targets 
discrete sites for DSBs. These sites are predominantly genic; 90% of the AID-
dependent rearrangement partners of IgH are in genes. We can detect 
rearrangements to the transcription start sites of nearly 100 different genes that 
are actively transcribed. This is consistent with many studies showing that AID is 
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associated with transcription (Jung et al., 1993; Stavnezer-Nordgren and Sirlin, 
1986; Yoshikawa et al., 2002), and with the positions of sequenced c-myc/IgH 
translocations in primary B cells (Robbiani et al., 2008). 
 
The TSS is a site enriched in ssDNA (Nechaev et al., 2010; Zhang and Gralla, 
1989); this appears to be the primary site of AID activity genome-wide, which is 
consistent with studies demonstrating AID activity on ssDNA in vitro and in vivo 
(Bransteitter et al., 2003; Chaudhuri et al., 2003; Dickerson et al., 2003; 
Petersen-Mahrt et al., 2002; Pham et al., 2003; Ramiro et al., 2003; Sohail et al., 
2003). While genes rearranged by AID are transcribed, expression (as measured 
by mRNA-Seq) does not correlate directly with rearrangement frequency. This 
suggests that transcription is necessary but not rate-limiting for rearrangement. 
Rather, PolII stalling is the likely mechanism for AID targeting. This is reflected in 
the distribution of AID and its co-factor Spt5 in the genome (Pavri et al., 2010; 
Yamane et al., 2011), and that AID-dependent rearrangements occur mainly on 
transcription start sites of stalled genes that carry high levels of the PolII stalling 
factor Spt5.  
 
Interestingly, The AID-dependent rearrangement partners of c-myc and IgH 
appear largely similar. We observe a bias for intra-chromosomal joining of AID 
targets to I-SceI sites. But, for extra-chromosomal AID targets, we observe no 
such effect. This might be due to a shared nuclear compartment of c-myc, IgH 
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and most AID-targeted genes (which are transcribed). Their mutual physical 
proximity may be facilitating similar trans-chromosomal rearrangement profiles. 
Given the demonstrated physical proximity of IgH and c-myc (Roix et al., 2003) 
and the tendency of transcribed regions to interact (Lieberman-Aiden et al., 
2009), transcription-associated genomic organization may mediate this 
phenomenon. 
 
A recent study using Nbs1 ChIP-on-ChIP as a surrogate for DNA damage 
suggested that AID targets repeat rich sequences (Staszewski et al., 2011). 
These were proposed to occur specifically at CA repeats, non-CA tandem 
repeats and SINEs. In contrast, we find no AID-dependent increase in 
rearrangements to these, or any other, non-Ig repeats. This is consistent with AID 
and Spt5 ChIP-Seq studies, which failed to note any loading at these sites. 
Moreover, AID-dependent rearrangement hotspots predominantly occur in genes, 
not in or near repeat regions that are not transcribed.  
 
In addition, we find a strong correlation between hypermutation and 
rearrangements, suggesting that genes susceptible to AID mediated DSBs are a 
subset of the most highly mutated genes in the genome. Consistent with this 
notion, we show that Pax5, Il21r, Gas5, Ddx6, Birc3, Ccnd2, Aff3, Grhpr, c-myc, 
Pvt1, Bcl2l11, Socs1, mir142, Junb and Pim1, which are translocated or deleted 
in mature B cell lymphomas, and are among the more highly mutated AID 
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targets, bear AID-dependent translocation hotspots. This suggests that in 
addition to hypermutation, AID is a major source of genomic instability in these 
cancers. Many of the mature B cell lymphomas are thought to originate in the 
germinal center, which is the primary site of AID expression and activity 
(Kuppers, 2005; Muramatsu et al., 1999). And, many of the AID-initiated 
translocations we describe are recurrent and clonal in these tumors. In line with 
data showing that AID is oncogenic in vivo (Robbiani et al., 2009), we suggest 
that AID can initiate genomic rearrangements essential for mature B cell 
lymphomagenesis. It should be noted that our experiments were performed on in 
vitro stimulated B cells. Germinal center B cells may have an alternate gene 
expression profile that influences the number and position of AID target sites. 
This may account for the absence of some genes from our hotspot lists known to 
be translocated in mature B cell lymphoma.  For example, we do not detect the 
Bcl6/IgH translocation observed in diffuse large B cell lymphoma (Ye et al., 
1995). As such, to further extend these studies and capture the entire 
complement of IgH translocation partners, we propose that TC-Seq might be 





Finally, we propose that TC-Seq can be adapted for use in other cell types and 
systems to study translocation biology, nuclear architecture and the mechanics of 
other DNA damaging enzyme, chemicals and conditions.  
 
Translocation profiles of other cell types. Recurrent translocations appear in 
tumors other than mature B cell lymphomas. For example, most mucoepidermoid 
carcinomas harbor the MECT1-MAML2 gene rearrangement and in many 
prostate cancers TMPRSS2 is found fused to the ERG gene (Clark and Cooper, 
2009; Hunt, 2011). In this study we have examined the rearrangement profile of 
IgH, and thereby have revealed the mechanisms of its rearrangement. We 
propose that examining the recombination profile of DSBs in rearrangement-
prone genes of other cell types might reveal the forces underlying their behavior. 
TC-Seq can be performed in any cell culture, so these experiments would simply 
require that the cell type of interest be isolated and grown.  
 
Examining junctional microanatomy. TC-Seq relies on paired-end Illumina 
sequencing to identify the I-SceI containing locus and a sequence displaced from 
the partner sequence breakpoint; 36 nucleotides are read from each end of each 
molecule. This sequencing modality has the advantage of extremely high 
throughput, using latest-generation chemistry each run can yield greater than 240 
million reads. Such a quantity of data allows us to assay tens of million of cells 
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concurrently while ensuring complete saturation, thereby facilitating highly 
powered studies of rare events. However, Illumina paired-end sequencing does 
not allow for sequencing through breakpoints. High throughput breakpoint 
analysis would yield information about junctional microanatomy (deletion, 
microhomology utilization and insertion) thereby allowing us to distinguish 
between NHEJ and alt-NHEJ mediated events. First, one could explore the 
relative contributions of these two pathways to the unselected rearrangement 
landscape in primary cells. Second, these experiments could be performed in the 
absence of DNA repair factors to investigate their contribution to aberrant joining 
in these two pathways. 
 
To obtain such data one needs at least 300 bp continuous sequencing reads, 
through the entire fragmented DNA molecule. An alternative sequencing 
technology, 454 sequencing, performs 400 bp continuous reads that would allow 
such an analysis. Unfortunately, this technology is merely medium-throughput (1 
million reads per run), so much less power can be achieved in these analyses. 
We have successfully adapted TC-Seq for use with a 454 sequencer and are 
exploring the genome-wide landscape of junctional microanatomy. 
 
Mapping common fragile sites. Common fragile sites are areas of the genome 
damaged during partial replicative stress. While about 80 of these sites are 
currently known, they are generally coarsely mapped. While a sequence feature 
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is likely to underlie this phenomenon the exact cause of their emergence is 
incompletely defined (Durkin and Glover, 2007). These sites are documented to 
partner in rearrangements (Burrow et al., 2009). We propose that TC-Seq can be 
employed to map rearrangements that arise after treatment with aphidicolin, a 
drug that induces DSBs at fragile sites (Glover et al., 1984). In this way, the exact 
nature and location of fragile sites can be determined. 
 
A silent gene recombinome. TC-Seq data has revealed that c-myc and IgH, both 
transcribed genes, tend to rearrange to other transcribed genes. Since the 
composite density analysis of genic rearrangements reveals a bias to the 
transcription start site, ssDNA fragility may be a partial determinant of this bias. 
However, what role genomic architecture plays in this trend is unknown. We 
propose that obtaining the recombinome for a DSB in a silent gene could reveal 
the relative roles of ssDNA instability and spatial proximity in this phenomenon. 
We expect that if differential localization of transcribed and non-transcribed 
genes impacts rearrangement profiles, a DSB in a silent gene should recombine 
less frequently than a DSB in an active gene to other transcribed genes. Such an 
experiment could be performed by generating a knockout mouse with an I-SceI 
site in a gene silent in B cells, or by performing TC-Seq on IgH in a cell type in 
which it is unexpressed. 
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Exploring RAG-induced non-Ig DSBs. RAGs may catalyze non-Ig DSBs. These 
DSBs may participate in rearrangement observed in B cell lymphomas 
(Vaandrager et al., 2000). However, the spectrum of RAG targeting is unknown. 
TC-Seq may be adapted to discover these targets. We propose that pre-B cells 
bearing I-SceI sites may be isolated from mouse bone marrow and infected with 
Ablson virus, thereby immortalizing and freezing them in an early large pre-B cell 
stage in which RAGs are not expressed (Muljo and Schlissel, 2003). 
Administration with STI-571 (Gleevec) will allow cells to differentiate into the late 
pre-B cell stage and enforce RAG expression (Muljo and Schlissel, 2003). At this 
time cells can be infected with I-SceI to generate RAG-mediated rearrangements 
to that site.  
 
RAG function differs substantially from AID. While AID has no known end 
protection function, RAG2 shepherds DSBs to faithful joining by the NHEJ 
pathway (Corneo et al., 2007). Thereby, RAG-generated ends may be less 
amenable to rearrangement generation than AID generated ends. coreRAG2 
released DNA ends may be more available to aberrant joining (Corneo et al., 
2007; Deriano et al., 2011); we propose that using this RAG2 mutant in TC-Seq 





CHAPTER 7:  
Methods 
 
B Cell Cultures, Infections and Sorting 
 
Resting B lymphocytes were isolated from mouse spleens by immunomagnetic 
depletion with anti-CD43 MicroBeads (Miltenyi Biotech) and cultured at 0.5 × 106 
cells/ml in RPMI supplemented with L-glutamine, sodium pyruvate, 
antibiotic/antimycotic, HEPES, 50 μM 2-mercaptoethanol (all from GIBCO-BRL), 
and 10% fetal calf serum (Hyclone). B cells were stimulated in the presence of 
500ng/ml RP105 (BD Pharmingen), 25 μg/ml lipopolysaccharide (LPS) (Sigma) 
and 5 ng/ml mouse recombinant IL-4 (Sigma). Retroviral supernatants were 
prepared by cotransfection of BOSC23 cells with pCL-Eco and pMX-IRES-GFP-
derived plasmids encoding for I-SceI-mCherry or AID-GFP with Fugene 6, 72 hr 
before infection. At 20 and 44 hr of lymphocyte culture, retroviral supernatants 
were added, and B cells were spinoculated at 1150 g for 1.5 hr in the presence of 
10 μg/ml polybrene. For dual infection, separately prepared retroviral 
supernatants were added simultaneously on both days. After 4 hr at 37°C, 
supernatants were replaced with LPS and IL-4 in supplemented RPMI. At 96 hr 
from the beginning of their culture, singly infected B cells were collected and 
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frozen in 10 million cell pellets at -80C. Dually infected B cells were sorted for 
double positive cells with a FACSAria instrument (Becton Dickson) then frozen 
down. 
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Translocation Capture Sequencing (TC-Seq) 
 
Genomic DNA Extraction and Sonication 
 
5x10 million B cell aliquots were thawed on ice. Cells were resuspended in 100ul 
of Phosphate buffered saline (PBS) and transferred to a 15ml conical tube 
containing 5mL Proteinase K buffer (100mM Tris pH8, 0.2% SDS, 200mM NaCl, 
5mM EDTA) and 50ul of 20mg/ml Proteinase K. Cells were digested overnight at 
55C. To extract DNA, addition of 5mL of phenol-chloroform was followed by 30s 
of gentle inversion and 20 minutes of centrifugation at 4000rpm. The aqueous 
phase was transferred to a 50ml conical tube containing 12.5mL of 100% 
ethanol. The mixture was centrifuged for 15 minutes at 4000rpm at 4C. The pellet 
was washed twice with 5mL 70% ethanol, transferred to a microcentrifuge tube, 
air dried for 5 minutes and resuspended in 100uL 10mM Tris pH8 with 1uL of 
0.5mg/ml DNAse-free RNAse (Roche). Genomic DNA concentration was 
adjusted to 167ng/uL with 10mM Tris pH8 and divided into microcentrifuge tubes 
containing 300uL each. Genomic DNA was fragmented by sonication at low 
power for 7 cycles (30” on/30” off) in a Bioruptor (Diagenode)  to yield a 500-
1350bp distribution of DNA fragments. DNA was further divided into 50x30ul 
(5ug) aliquots in 1.5mL eppendorf tubes.   
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Genomic DNA Fragment Preparation, Linker Ligation and Elimination of 
Unrearranged Loci 
 
Each experiment consisted of genomic DNA from 50 million B cells in 50 x 5ug 
aliquots for a total of 250ug of fragmented genomic DNA. The following reactions 
were performed individually on 5ug aliquots. DNA was blunted by End-It DNA 
Repair Kit (Epicentre) then purified by Qiagen PCR purification column and 
eluted in 43uL of Buffer EB. Blunted DNA was adenosine-tailed by addition of 5ul 
10x NEB2 buffer, 1uL 10mM dATP and 2uL Klenow fragment 3->5’ exo- (NEB) 
followed by incubation at 37C for 1hr. Each reaction was purified by Qiagen PCR 
purification kit and eluted in 40uL of Buffer EB. Each aliquot of blunted, A-tailed 
DNA fragments was ligated to 200pmol of linkers by addition of 4uL linker, 5uL 
NEB T4 DNA ligase buffer and 1uL high concentration T4 DNA ligase (NEB) 
followed by incubation overnight at 16C. Ligase was inactivated by incubation at 
70C for 20 minutes, reactions were purified by Qiagen PCR purification column 
and eluted in 44uL Buffer EB. Native loci were eliminated by adding 5uL 10x NEB 
Isce1 buffer, 0.5uL 100x BSA and 1uL I-Sce1 then incubating the reaction at 37C 
for 2 hours. Each reaction was purified by Qiagen PCR purification column and 





PCR Round 1 
 
Pooled linker-ligated DNA was divided into 2 equal parts for semi-nested ligation-
mediated PCR using either forward or reverse primers.  Forward and reverse 
enrichment streams are kept separate for the entire remainder of the protocol. 
DNA was divided into 1ug aliquots and mixed with 20ul 5x Phusion HF buffer, 3ul 
10mM dNTPs, 1ul 20uM biotinylated pMycF1, pMycR1, pIgHF1 or pIgHR1, 1uL 
of Phusion Taq (Finnzymes) and H2O to 100uL. Single-primer PCR reactions 
were run – 1x(98C-1min) 12x(98C-15sec, 65C-30sec, 72C-45sec) 1x(72C-1min) 
1x(4C-forever) - then each tube was spiked with 1ul 20uM pLinker and subjected 
to additional cycles of PCR - 1x(98C-1min) 35x(98C-15sec, 65C-30sec, 72C-
45sec) 1x(72C-5min) 1x(4C-forever). Forward and reverse PCR reactions were 
pooled separately, and 400uL of each was purified in 4 Qiagen PCR purification 
columns, each eluted in 50uL EB. All 200ul of each sample was run on a 2% 
agarose gel until well separated and appropriately size fragments [for IgHI: F 
(350bp-1kb) R (300-1kb), for MycI: F (300bp-1kb) R (300-1kb)] were excised. 
DNA was purified in Qiagen Gel purification columns and gel-based size 
selection was repeated once. 100uL of washed magnetic T1 magenetic 
streptavidin beads (Invitrogen) were resuspended in 400ul 2x B&W buffer (10mM 
Tris pH7.5, 1mM EDTA, 2M NaCl), 200ul was added to each forward and reverse 
PCR1 products and the mixture incubated for 1hr with gentle nutation at room 
temperature.  Beads were isolated, washed 3x in 500uL 1x B&W buffer, 1x in 
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ddH2O and resuspended in 87ul H2O. Unrearranged loci were further eliminated 
by adding 10ul 10x NEB Isce1 buffer, 1ul 100x BSA and 2uL Isce1, then 
digesting DNA on beads for 2 hours at 37C. Beads were washed 3 times in 1x 
B&W, once in H2O and resuspended in 50uL H2O.   
 
Round 2 PCR 
 
 20ul of beads from each of the forward and reverse PCR1 was separately mixed 
with 40ul 5x Phusion HF buffer, 6ul 10mM dNTPs, 2ul 20uM pIgHF2, pIgHR2, 
pMycF2 or pMycR2, 2uL 20uM pLinker, 2ul Phusion taq and 128ul H2O then 
separated into 50ul aliquots and subjected to PCR - 1x(98C-1min) 35x(98C-
10sec, 65C-30sec, 72C-40sec) 1x(72C-5min) 1x(4C-forever). PCR reactions 
were separated from beads and each tube was run on one lane of a 2% agarose 
gel until appropriate separation was achieved. Desired fragment sizes were 
excised [for IgHI: F (300bp-1kb) R (250-1kb), for MycI: F (270bp-1kb) R (270-
1kb)] and purified by Qiagen gel purification column. Size selection was repeated 
once more in 4 Qiagen gel purification columns for each forward and reverse; 
each column was eluted with 30uL EB. 
 
Preparing Enriched DNA for Paired-end High Throughput Sequencing 
 
120ul of isolated DNA was mixed with 13uL 10x NEB Buffer 4, 2uL of Asc1 and 
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H2O to 150ul then incubated at 37C for 2 hours to cleave the linker off enriched 
products. Restriction digests were purified by Qiagen PCR purification column 
and redigested with Asc1 to ensure complete linker removal. Desired fragment 
sizes [for IgHI: F (250bp-1kb) R (200-1kb). for MycI: F (220bp-1kb) R (220-1kb)] 
were isolated by eletrophoresis on a 2% agarose gel and isolated by Qiagen gel 
purification column. DNA was blunted by End-It DNA Repair Kit (Epicentre), 
column purified, A-tailed as described above and ligated to Illumina paired end 
adapters. Ligation reactions were column purified then run on a 2% agarose gel 
and desired fragment sizes isolated [for IgHI: F (320bp-1kb) R (270-1kb), for 
MycI: F (300bp-1kb) R (300-1kb)] (Note, at this point the product may not be 
visible on the gel). Adapter ligated fragments were enriched by 25 cycles of PCR 
with Illumina PCR primers PE1.0 and PE2.0 and desired fragment sizes isolated 
on a 2% agarose gel [for IgHI: F (400bp-1kb) R (350-1kb), for MycI: F (380bp-
1kb) R (380-1kb)]. Samples were confirmed to be enriched for rearranged loci by 
TOPO cloning and screening 10 forward- and 10 reverse-enrichment colonies. 
Finally, appropriate size distribution was confirmed by Agilent Bioanalyzer. 
Forward and reverse libraries for the same sample were mixed in equimolar 






Mapping of Translocation Hotspots 
 
A translocation hotspot was defined as a localized enrichment of translocation 
events above what is expected from the null hypothesis of uniform distribution of 
translocation events along the genome. To identify such hotspots, candidate 
regions were defined as locations containing consecutive translocations with 
distances shorter than expected from the mappable size of the mm9 genome 
assembly (P < 0.01 each as determined by a negative binomial test). For a 
candidate region to be called a hotspot it had to (1) have more than 3 
translocations and (2) have at least one read from each of the two sides of the 
bait and (3) have at least 10% of the translocations come from each side of the 
bait and (4) have a combined P value less than 10-9 given the number of 
translocations and length of the region as determined by a negative binomial test. 
Hotspots with a large degree (>80%) of overlap with repeat regions or small 
footprints (<100nt) were removed. For AID-dependent hotspot lists hotspots with 
less than 10-fold enrichment over the AID-/- control were removed. Analyses of 
RNA-Seq, chromatin modifications, AID-, PolII-, and Spt5-ChIP as well as the 
identification of cryptic I-SceI sites, TSSs, genic and intergenic domains were 





CD43- splenocytes from IgkAID-Ung-/- or Aicda-/- mice were cultured at 0.1 x 106 
cells/ml with LPS+IL-4, and 0.5 mg/ml of aCD180 (RP105) antibody (RP/14, BD 
Pharmingen). At 72 hrs cells were diluted 1:4 and cultured for another 48 hs. 50 
ng of genomic DNA was amplified for 30 cycles with Phusion DNA polymerase 
(New England Biolabs) and specific primers. For nested PCR, two-20 cycle 
amplifications were performed with DMSO. The amplicon was cloned using PCR 




50mM double stranded asymmetric linker (dsaLinker) was generated by mixing 
equimolar parts of pLT and pLB in annealing buffer (10 mM Tris, pH 8.0, 50 mM 
NaCl, 1 mM EDTA), heating the mixture to boiling, then incubating it at room 
temperature for 2 hours.  
 
Table 7.1. Primers for TC-Seq. 










































Table 7.2. Primers for hypermutation analysis. (Pages 150-151) 
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